bismuth has been researched along with Infections, Helicobacter in 919 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.11) | 18.7374 |
| 1990's | 391 (42.55) | 18.2507 |
| 2000's | 174 (18.93) | 29.6817 |
| 2010's | 195 (21.22) | 24.3611 |
| 2020's | 158 (17.19) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY | 1 |
| Ang, D; Ang, TL; Lim, KW; Tan, M; Wong, YJ; Yih Wong, AS | 1 |
| Alcedo, J; Amador, J; Bujanda, L; Calvet, X; Castro-Fernández, M; Fernández-Salazar, L; Gené, E; Gisbert, JP; Lanas, Á; Lucendo, AJ; Molina-Infante, J; Nyssen, OP; Pérez-Aisa, A; Puig, I | 1 |
| Arcidiacono, PG; Armuzzi, A; Bazzoli, F; Biagi, F; Cannizzaro, R; Cavestro, GM; Ciacci, C; Dajti, E; Frazzoni, L; Marasco, G; Monica, F; Peralta, S; Radaelli, F; Romano, M; Zagari, RM | 1 |
| Dao, HV; Dao, LV; Dat, VQ; Hoang, LB; Nguyen, HT; Nguyen, HTV; Nguyen, TD; Tran, ATN; Vu, VT | 1 |
| Cho, JH; Jin, SY; Park, S | 1 |
| Dutta, AK; Phull, PS | 1 |
| Cao, Y; Huo, L; Liu, J; Liu, Y; Lv, H; Qi, Y; Shi, Y; Wang, J; Wang, L; Wei, X; Zhang, J; Zhang, L | 1 |
| Cao, Y; He, W; Li, X; Wang, J | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| An, P; Chen, ZF; Ding, XW; Guan, JL; He, Q; Hu, YL; Li, PY; Long, H; Luo, HS; Wu, SS; Xiong, JG; Zhou, L | 1 |
| Fan, J; Guan, J; Han, B; Jia, X; Li, M; Qi, R; Wang, H; Wang, Q; Xie, Z; Xu, Y; Xue, R; Yu, H; Yu, W | 1 |
| Baik, GH; Bang, CS; Jang, HJ; Kae, SH; Kim, HY; Kim, J; Lee, SP; Lim, H; Seo, SI; Shin, WG; Yang, YJ | 1 |
| Ding, SZ; Hu, RB; Jia, BL; Lan, L; Ma, J; Qi, YB; Shao, QQ; Wei, PR; Xiao, W; Yu, M; Yu, XC; Yuan, L; Zhang, LZ; Zhao, JB | 1 |
| Apostolopoulos, P; Argyriou, K; Christodoulou, DK; Georgopoulos, SD; Giouleme, O; Kotzampassi, K; Koustenis, K; Liatsos, C; Mantzaris, GJ; Moutzoukis, M; Mylonas, II; Poutakidis, C; Stogiannou, D; Tseti, I; Veretanos, C; Viazis, N | 1 |
| Hubscher, E; Jacob, R; Pelletier, C; Shah, S; Vinals, L; Yadlapati, R | 1 |
| Continisio, A; D'Abramo, FS; Di Leo, A; Ierardi, E; Losurdo, G; Piazzolla, M; Pricci, M; Rima, R | 1 |
| Inge, AK; Nero, M; Rooth, V; Svensson Grape, E; Willhammar, T | 1 |
| Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R | 1 |
| De Reuse, H; Kumar, S; Vinella, D | 1 |
| Antonowicz, S; Dabrowski, A; Daniluk, J; Gugnacki, P; Krzyzak, M; Maslach, D; Mlynarczyk, M; Rogalski, P; Swidnicka-Siergiejko, A; Wasielica-Berger, J | 1 |
| Huang, W; Lei, X; Li, H; Li, J; Xu, D; Xu, G; Yin, Z; Zhang, J | 1 |
| Mladenova, I | 1 |
| Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT | 1 |
| Cheng, S; Chi, J; Li, H; Liu, P; Liu, X; Luo, J; Qu, P; Xia, X; Xie, X; Xu, C; Yang, H; Zhao, W | 1 |
| Ding, YM; Duan, M; Han, ZX; Ji, R; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 1 |
| Abbondio, M; Bibbò, S; Dore, MP; Loria, M; Niolu, C; Pes, GM; Sau, R; Tanca, A; Uzzau, S | 1 |
| Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK | 1 |
| Ayvaz, MA; Koroglu, M; Ozturk, MA | 1 |
| De Reuse, H; Duchateau, M; Giai Gianetto, Q; Gorgette, O; Guigner, JM; Kumar, S; Marbouty, M; Matondo, M; Schmitt, C | 1 |
| Choe, Y; Kim, BW; Kim, JS; Kim, MJ; Na, SY | 1 |
| Almeida, N; Bastos, I; Branquinho, D; Calhau, C; Correia, C; Fernandes, A; Figueiredo, P; Gravito-Soares, E; Leal, C; Vasconcelos, H | 1 |
| Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X | 1 |
| Dong, XY; Du, YQ; Li, ZS; Wu, Y; Zhou, XZ | 1 |
| Li, T; Zhou, Y | 1 |
| Andreev, DN; Bektemirova, LG; Dicheva, DT; Maev, IV; Mkrtumyan, AM | 1 |
| Iakovenko, AV; Ivanov, AN; Soluyanova, IP; Strokova, TV; Vasilyev, NN; Yakovenko, EP | 1 |
| Li, CL; Lu, HP; Ren, XL; Song, ZQ; Suo, BJ; Tian, XL; Yao, XY; Zhang, H; Zhang, YX; Zhou, LY | 1 |
| Kim, GH; Lee, MW | 1 |
| He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL | 1 |
| Hei, QW; Ji, YH; Qi, YX; Shi, YM; Sun, DL; Sun, JM; Wu, T; Yang, XF | 1 |
| Guo, Q; He, C; Huo, L; Lu, N; Lyu, B; Shu, X; Xie, Y; Xiong, Z; Yu, Y; Zhang, Z; Zhu, Y; Zhuang, K | 1 |
| Du, Q; Han, Y; Li, Y; Lou, G; Lu, L; Wang, Y; Yan, H; Ye, J | 1 |
| Huang, J; Lin, Y | 1 |
| Chen, J; Ding, S; Li, T; Liu, Y; Shao, F; Wang, L; Xie, L; Zhang, Z; Zhou, C; Zhou, S; Zhu, B; Zhu, J | 1 |
| Hu, Y; Lu, NH; Zhu, Y | 3 |
| Ding, YM; Duan, M; Han, ZX; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Mu, YJ; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 2 |
| Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC | 1 |
| Bellini, M; Borghi, C; Di Leo, A; Dore, MP; Farinati, F; Fiorini, G; Franceschi, F; Gasbarrini, A; Gatta, L; Ghisa, M; Gisbert, JP; Granata, L; Gravina, AG; Holton, J; Losurdo, G; Mégraud, F; Nardone, G; Nyssen, OP; O'Morain, C; Pavoni, M; Pellicano, R; Puig, I; Rocco, A; Romano, M; Saracino, IM; Vaira, D | 1 |
| Chen, Y; Lu, H; Lyu, B; Song, Z; Wang, J; Xia, J; Zhao, Z; Zhou, L | 1 |
| Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Chehter, EZ; de Moraes Andrade, PV; Monteiro, YM | 1 |
| Love, BL; Yunusa, I | 1 |
| Dang, YN; Gao, X; Li, LR; Li, WJ; Li, X; Qian, HS; Xu, XB; Yang, Z; Yuan, L; Zhang, GX; Zhang, M; Zhang, WF | 1 |
| Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L | 2 |
| Abavisani, M; Azadbakht, MK; Barani, M; Fathizadeh, H; Feizabadi, MM; Khaledi, M; Kodori, M; Moghadaszadeh, M; Neamati, F; Zeinali, M | 1 |
| Boal Carvalho, P; Cotter, J; Freitas, M; Lima Capela, T; Macedo Silva, V; Magalhães, J | 1 |
| Liang, M; Shi, J; Yuan, B; Zhao, P; Zhu, C; Zhu, X | 1 |
| Chen, CL; Chen, KY; Chuah, SK; Graham, DY; Hsu, PI; Kao, JY; Kuo, CH; Lee, CL; Lee, HC; Liu, YH; Shie, CB; Shiu, SI; Tai, WC; Tsay, FW; Wu, DC; Yamaoka, Y; Yang, JC; Yeh, HZ | 1 |
| Hu, Y; Li, YQ; Liu, XW; Lu, NH; Wang, H; Wang, JB; Wang, QZ; Xie, Y; Zhang, DK; Zhang, ZY; Zhu, Y | 1 |
| Chen, J; Chen, X; Ding, Z; Han, Y; Huang, Y; Liang, X; Lu, H; Xu, F; Zeng, X | 1 |
| Chen, ZY; Han, JL; Han, XY; Huang, XX; Lan, C; Li, PY; Li, YQ; Liu, DN; Mo, CY; Pan, J; Tan, Y; Tang, J; Wang, QY; Wu, DH; Yang, WZ | 1 |
| Chua, EG; Gao, X; Han, X; Lai, B; Marshall, BJ; Tay, CY; Wang, X; Wei, X; Yu, X; Zhang, X | 1 |
| Chen, J; Ding, Z; Guo, Y; Han, Y; Huang, Y; Liang, X; Lu, H; Wang, J; Xu, P | 1 |
| Chung, JW; Kim, JS; Kim, TH; Ko, W | 1 |
| Chen, DL; Chen, YL; Li, ZS; Zhang, HQ | 1 |
| Chen, HW; Liu, JJ; Lu, Y; Peng, X; Su, PZ; Wan, Y; Yao, JY; Yu, J; Zhang, M; Zhi, M | 1 |
| Fan, LL; Guo, Y; He, P; Hu, J; Lan, CH; Liu, YX; Mei, H; Pan, J; Su, NY; Sun, WJ; Wang, XW; Zhang, DK; Zou, PY | 1 |
| Chouhan, MI; Hallur, VK; Kumar, C; Makashir, MS; Nayak, HK; Padhy, BM; Panigrahi, MK; Samal, SC; Sethi, S | 1 |
| Kim, JH; Lee, SY; Park, HS; Sung, IK | 1 |
| Ding, YM; Li, YY | 1 |
| Hu, B; Huanfei, D | 1 |
| Chan, P; Cheung, K; Deng, Z; Han, S; Li, K; Li, Y; Luo, X; Lyu, T; Ni, L | 1 |
| Czerniak, R; Gu, L; Hu, C; Men, R; Miao, J; Tang, J; Wang, W; Wang, Y; Yang, L; Yoshida, N | 1 |
| Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
| Du, Q; Li, Y; Liao, O; Liu, X; Lou, G; Wang, Y; Wu, H; Wu, Y; Ye, J | 1 |
| Bai, FH; Chen, C; Chen, RX; Chen, SJ; Huang, SM; Li, D; Zeng, F; Zhang, DY; Zhang, XD | 1 |
| Guerra, W; Moreira, FH; Rosa, LHF; Rosário, JDS; Silva-Caldeira, PP | 1 |
| Ang, TL; Aye, TT; Basir, DN; Lee, YY; Luu, MN; Mahachai, V; Miftahussurur, M; Quach, DT; Sollano, JD; Vannarath, S; Vilaichone, RK; Vutha, K | 1 |
| Huang, L; Li, A; Li, K; Lin, K; Wang, Y; Yang, S; Ye, Y | 1 |
| Eiamsitrakoon, T; Graham, DY; Mahachai, V; Ratana-Amornpin, S; Sanglutong, L; Siramolpiwat, S | 1 |
| Almajano, EA; Babayeva, G; Boltin, D; Bordin, DS; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzás, GM; Cano-Català, A; Capelle, LG; Castro-Fernandez, M; Denkovski, M; Doulberis, M; Fiorini, G; Gasbarrini, A; Gisbert, JP; Gridnyev, O; Jonaitis, L; Jonaitis, P; Keco-Huerga, A; Kupcinskas, J; Lanas, Á; Leja, M; Lerang, F; Lucendo, AJ; Mahmudov, U; Marcos-Pinto, R; Marlicz, W; Martínez-Domínguez, SJ; Matysiak-Budnik, T; Mégraud, F; Milivojevic, V; Moreira, L; Nyssen, OP; O'Morain, C; Pabón-Carrasco, M; Pérez-Aísa, Á; Phull, PS; Rodrigo, L; Rokkas, T; Saracino, IM; Šembera, Š; Şimşek, H; Smith, SM; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzanina, L; Voynovan, I | 1 |
| Gao, W; Wang, L; Yin, Y; Zhang, X; Zhu, M | 1 |
| Cho, KB; Jung, HR; Kim, SW; Lee, JW; Lee, JY; Lee, YJ; Park, M | 1 |
| Fan, X; Lu, D; Yao, G | 1 |
| Ou, S; Xu, Y; Yang, T; Yao, J; Yuan, X; Zuo, X | 1 |
| Dong, RN; Feng, LN; Guan, JL; Han, YY; Huang, YJ; Li, JY; Li, PY; Liao, JZ; Xia, SH; Zhang, MY; Zhang, Y; Zhao, K | 1 |
| Jiang, Y; Lv, Y; Qin, X; Wang, X; Yang, P; Yu, J | 1 |
| Cai, X; Lu, J; Song, H; Sun, Q; Yuan, C; Zeng, M; Zhou, S | 1 |
| Cho, SJ; Kim, JY; Kim, SG | 1 |
| Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z | 1 |
| Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J | 1 |
| Chotivitayatarakorn, P; Poonyam, P; Vilaichone, RK | 1 |
| Gisbert, JP; Mcnicholl, AG | 1 |
| Ciancio, A; Ponzetto, A; Riva, P | 1 |
| Arenas, A; Camargo, MC; Echeverría, A; Fuentes-López, E; Harris, P; Jorquera, A; Lavanderos, M; Maquilón, S; Pizarro, M; Quiñones, L; Ríos, C; Riquelme, A; Rojas, L; Sandoval, M; Sepúlveda, R; Serrano, C | 1 |
| Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
| Huang, Y; Jiang, Y; Tang, Z; Wang, Y; Yan, W; Ye, Z; Zhang, Y; Zhou, Y | 1 |
| Avramenko, AA | 1 |
| Lee, YC; Liou, JM; Wu, MS | 2 |
| Graham, DY; Huang, Y; Ji, Y; Liang, X; Lu, H; Luo, L; Yu, L | 1 |
| Kim, N; Lee, DH; Lee, JW; Park, YS; Shin, CM; Yoon, H; Yoon, K | 1 |
| Cogdill, AG; Guevara, B | 1 |
| Alcaide, N; Areia, M; Ariño, I; Axon, T; Barrio, J; Bordin, D; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzas, G; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernández, M; Dominguez-Cajal, M; Garre, A; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Kunovský, L; Kupcinskas, L; Lamy, V; Leja, M; Lerang, F; Lucendo, A; Marcos Pinto, R; María Botargues Bote, J; Mégraud, F; Milosavljevic, T; Modolell, I; Niv, Y; Nyssen, OP; O'Morain, C; Ortuño, J; Pérez Lasala, J; Pérez-Aisa, Á; Perona, M; Phull, P; Przytulski, K; Rodrigo-Sáez, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Voynovan, I | 1 |
| Avallone, L; Bazzoli, F; Compare, D; Dallio, M; Federico, A; Granata, L; Gravina, AG; Loguercio, C; Martorano, M; Miranda, A; Mucherino, C; Nardone, G; Priadko, K; Romano, L; Romano, M; Romiti, A; Romito, MR; Sgambato, D; Tuccillo, C; Zagari, RM | 1 |
| Chang, WL; Cheng, HC; Hsieh, MT; Kuo, HY; Lin, MY; Sheu, BS; Tsai, YC; Wu, CT; Yang, HB | 1 |
| Bordin, DS; Embutnieks, YV; Megraud, F; Nyssen, OP; O Morain, C; Perez-Gisbert, J; Voynovan, IN | 1 |
| Andreev, DN; Bektemirova, LG; Dicheva, DT; Lobanova, EG; Maev, IV; Veliev, AM; Zaborovskii, AV | 1 |
| Cheng, L; Feng, R; Ma, X; Su, Y; Wang, W; Xu, H; Yang, Y; Zhang, D | 1 |
| Antonelli, G; Borghi, C; Cavallo, R; Fiorini, G; Lazzarotto, T; Pavoni, M; Saccomanno, L; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Chen, J; Chen, Q; Fang, HM; Huang, YT; Kan, LD; Li, LC; Qiu, Y; Yu, XL | 1 |
| Huang, Y; Lu, J; Lu, X; Miao, S; Sun, H; Wang, Y; Wu, J; Ye, Z; Zhou, Y | 1 |
| Alcaide, N; Barrio, J; Bujanda, L; Burgos, D; Caldas, M; Calvet, X; Castro, M; de la Coba, C; Di Maira, T; Dominguez-Cajal, M; Fernandez, N; Fernández-Salazar, L; Ferrer, L; Figuerola, A; Garre, A; Gisbert, JP; Gomez Rodriguez, BJ; Gomez, B; Gomez-Camarero, J; Hinojosa, J; Huguet, JM; Jimenez-Moreno, M; Lucendo, A; Mata Romero, P; Megraud, F; Modollel, I; Molina-Infante, J; Nyssen, OP; O'Morain, C; Ortuño, J; Perez-Aisa, A; Perona, M; Pozzati, L; Puig, I; Resina, E; Rodrigo, L; Tito, L; Varela, P | 1 |
| Calvo, PL; Cisarò, F; Pizzol, A | 1 |
| Bazzoli, F; Frazzoni, L; Fuccio, L; Marasco, G; Zagari, RM | 1 |
| Abbas, Z; Asim, M; Baqai, K; Laique, N; Samejo, SA | 1 |
| Chi, JS; Gong, RJ; Kun, KX; Li, H; Liu, P; Liu, XM; Tian, DL; Wu, H; Xia, XJ; Xie, XR; Xu, CX; Zhang, LF | 1 |
| Hu, JN; Ji, CR; Ji, R; Li, LX; Li, YQ; Li, YY; Lin, MJ; Liu, J; Qiao, C; Qu, JY; Zuo, XL | 1 |
| Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ | 1 |
| Furuta, T; Gisbert, JP; O'Connor, A; O'Morain, C | 1 |
| Hu, F; Liu, Y; Teng, G; Wang, H; Wang, W; Wu, T | 1 |
| Arslan, M; Balamtekin, N; Günal, A | 1 |
| Mukhopadhyay, AK; Nandi, SP; Saxena, A | 1 |
| Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Chen, Y; Ke, H; Li, J; Liu, L; Lu, B; Wang, J; Wang, Z; Yang, C | 1 |
| Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
| Brglez Jurecic, N; Espada Sanchez, M; Gisbert, J; Mégraud, F; O'Morain, C; Perez Nyssen, O; Tepes, B; Tepes, K | 1 |
| Ahn, JY; Choi, KD; Gong, EJ; Jung, HY; Jung, KW; Kim, DH; Lee, GH; Lee, JH; Na, HK; Pih, GY; Song, HJ | 1 |
| Areia, M; Castro-Fernandez, M; Fernanadez-Salazar, L; Fernandez-Bermejo, M; Gasbarrini, A; Gisbert, JP; Gomez-Rodriguez, BJ; Gravina, AG; Huguet, JM; Malfertheiner, P; Megraud, F; Nuñez, O; Nyssen, OP; O'Morain, C; Ortuñ, J; Pellicano, R; Perez-Aisa, A; Perona, M; Pinto, RM; Pozzati, L; Puig, I; Rodrigo, L; Romano, M; Vaira, D; Venerito, M | 1 |
| Mori, H; Suzuki, H | 1 |
| Coşkun Sökmen, F; Demirci, S; Kasapoğlu, B; Yozgat, A | 1 |
| Cao, NW; Chu, XJ; Guo, B; Li, BZ; Zhou, HY | 1 |
| Barcenilla Laguna, J; Bonoso Criado, R; Cabezudo Molleda, L; García Castro, MA; González de Castro, E; Maestro Antolín, S; Montero Moretón, Á; Moreira Da Silva, BA; Pérez Citores, L; Pérez Millán, AG; Santos Santamarta, F | 1 |
| Bozic, J; Bukic, J; Jukic, I; Leskur, D; Modun, D; Rusic, D; Seselja Perisin, A; Vukovic, J | 1 |
| Graham, DY; Howden, CW | 1 |
| Han, MH; Hwang, JY; Jeon, SW; Kim, C; Kwon, YH; Lee, JE; Nam, SY; Park, JH; Seo, AN | 1 |
| Barranco, R; Bautista-Villanueva, S; Galleani, C; García-Moguel, I; Herráez, L; Mielgo, R; Sotomayor-Contreras, JA | 1 |
| He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP | 1 |
| Alsamman, MA; Argueta, EA; D'Agata, EMC; Moss, SF | 1 |
| Li, Q; Liu, H; Rao, W; Tian, QJ; Xie, M; Zang, YJ; Zhang, B; Zhang, Q | 1 |
| Jeon, JY; Kim, B; Kim, MG; Kim, SY; Lee, J; Moon, SJ; Oh, K; Song, GS | 1 |
| Chung, WC; Kim, DB; Kim, YJ | 1 |
| Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X | 1 |
| Choi, IJ; Kim, CG; Kim, YI; Lee, JY; Park, B; Park, JY | 1 |
| Hu, J; Ji, C; Ji, R; Li, Y; Lin, B; Lin, M; Liu, J; Qi, Q; Qiao, C; Qu, J; Wan, M; Zuo, X | 1 |
| Chen, H; Huang, K; Jin, D; Kong, S; Ye, F; Zhang, G | 1 |
| Chen, CC; Chiang, TH; Graham, DY; Lee, YC; Liou, JM; Shun, CT; Tseng, PH; Wu, MS | 1 |
| De Francesco, V; Fiorini, G; Gatta, L; Manta, R; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Chang, EJ; Chang, YW; Jang, JY; Kim, JW; Moon, JC; Oh, CH; Shin, GY | 1 |
| Alekseenko, S; Areia, M; Barrio, J; Bordin, D; Bujanda, L; Buzas, GM; Caldas, M; Camarero, JG; Castro-Fernandez, M; Dekhnich, NN; Dominguez-Cajal, M; Fadeenko, G; Fernandez-Salazar, L; Georgopoulos, S; Gisbert, JP; Gomez Rodriguez, BJ; Heluwaert, F; Huguet, JM; Ilchishina, T; Jonaitis, L; Jurecic, NB; Kikec, Z; Kupcinskas, J; Lafuente, MR; Leja, M; Lerang, F; Lucendo, A; Machado, JC; Megraud, F; Modolell, I; Ntouli, V; Nuñez, O; Nyssen, OP; O'Morain, C; Ortuño, J; Pellicano, R; Perez-Aisa, A; Perez-Lasala, J; Perona, M; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, C; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Vologzhanina, L; Voynovan, I; Zaytsev, O | 1 |
| Huang, Y; Huang, Z; Shi, J; Tang, W; Wang, S; Wang, Y; Ye, Z; Zhang, P; Zheng, C; Zhou, Y | 1 |
| Argüelles Arias, F; Castro Laria, L; Caunedo Álvarez, Á; Fernández Álvarez, P; Gómez Rodríguez, BJ; Moreno Márquez, C; Valdés Delgado, T | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Bontems, P; Cadranel, S; Kotilea, K; Mahler, T; Miendje Deyi, VY; Nguyen, J; Salame, A; Verset, L | 1 |
| Alaa Eddin, K; Alassi, MW; Alhalabi, M; Cheha, K | 1 |
| Huang, L; Lu, N; Ouyang, Y; Wu, WK; Xie, C; Zeng, C; Zhang, L; Zhu, Z | 1 |
| Cao, ZQ; Chen, DF; Chen, GX; Du, Q; Fan, YH; Gan, C; Huo, XH; Jin, HF; Li, TW; Li, Y; Lyu, B; Ma, PP; Meng, J; Meng, LN; Sha, WH; Shi, ZH; Tang, XF; Wang, MT; Yang, P; Zha, AS | 1 |
| Li, SZ; Niu, ZY; Shi, YY; Xue, Y | 1 |
| Hu, JN; Ji, CR; Li, LX; Li, YY; Lin, BS; Lin, MJ; Liu, J; Qiao, C; Wan, M; Wang, J; Zha, J; Zuo, XL | 1 |
| Xiao, S; Yao, X; Zhou, L | 1 |
| Boyle, B; Brennan, D; Buckley, M; Crotty, P; Doyle, M; Farrell, R; Hussey, M; Kevans, D; Malfertheiner, P; McNamara, D; Megraud, F; Nugent, S; O'Connor, A; O'Morain, C; Smith, S; Weston, S | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Ding, Y; Fu, W; Song, Z; Suo, B; Tian, X; Wang, L; Xue, Y; Zhou, L | 1 |
| Abbasi, J | 1 |
| Chen, CY; Lyu, B; Wang, XT; Zhang, M | 1 |
| Akay, S; Akpinar, Z; Unsal, B | 1 |
| Ang, D; Ang, TL; Chew, CA; Lye, TF | 1 |
| Attaran, B; Graham, DY; Malekzadeh, R; Mohammadi, M | 1 |
| Davydkin, IL; Gricenko, TA; Osadchuk, AM | 1 |
| Gou, QY; Shi, RH; Yu, RB | 1 |
| Chen, A; Cheng, JS; Chuah, SK; Hsu, PI; Hsu, WH; Hu, HM; Kao, SS; Peng, NJ; Tsai, FW; Tsai, KW; Wang, YK; Wu, DC | 1 |
| Ang, TL; Aung, MM; Chakravuth, O; Chotivitayatarakorn, P; Fock, KM; Goh, KL; Graham, D; Harnsomburana, P; Kositchaiwat, C; Lee, YC; Leelakusolvong, S; Leow, A; Mahachai, V; Mairiang, P; Maneerattanaporn, M; Mya, SM; Pisespongsa, P; Pittayanon, R; Rani, A; Rasachak, B; Rojborwonwitaya, J; Sansak, I; Sollano, JD; Sugano, K; Syam, AF; Treeprasertsuk, S; Trong Quach, D; Vannarath, S; Vilaichone, RK; Wiwattanachang, O; Yamaoka, Y | 1 |
| Aguilera Castro, L; Albillos Martínez, A; Barreiro Alonso, E; de la Coba Ortiz, C; Ferre Aracil, C; Flores de Miguel, A; García García de Paredes, A; Jorge Turrión, MÃ; Marcos Prieto, HM; Martín de Argila de Prados, C; Pérez Álvarez, G; Rodríguez de Santiago, E; Rodríguez Escaja, C; Rodríguez Pérez, A | 1 |
| Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH | 1 |
| Andresen, V; Eisele, B; Frederking, D; Glocker, E; Günther, T; Miehlke, S; Morgner, A; Schröder, S | 1 |
| Gisbert, JP; Lamarque, D; O'Connor, A; O'Morain, C | 1 |
| Alvaro, D; Bellesia, A; Brambilla, G; Bresci, G; D'Angelo, A; De Francesco, V; Di Ciaula, A; Eramo, A; Londoni, C; Manta, R; Portincasa, P; Ridola, L; Sacco, R; Scaccianoce, G; Tanzilli, A; Vassallo, R; Zullo, A | 1 |
| Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A | 1 |
| Fiorini, G; Gatta, L; Pavoni, M; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH | 1 |
| Göktaş, Z; Kahramanoğlu Aksoy, E; Nazlıgül, Y; Pirinçci Sapmaz, F; Uzman, M | 1 |
| Bazzoli, F; Eusebi, LH; Rabitti, S; Zagari, RM | 1 |
| Abanades-Tercero, M; Andrés Esteban, EM; Blanco-González, JJ; Jordán-Castro, JA; Muñoz-Gómez, P; Valle-Muñoz, J | 1 |
| He, X; Li, H; Liao, X; Sun, H; Xia, W | 1 |
| De Francesco, V; Vaira, D; Zullo, A | 1 |
| Bishu, S; El-Zaatari, M; Grasberger, H; Kao, JY; Owyang, SY; Qian, JM; Tan, B; Yang, JC; Young, CL; Zhang, M | 1 |
| Morgando, A; Younes, R | 1 |
| Randel, A | 1 |
| Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ | 1 |
| Coşkun, DÖ; Deniz, K; Gürsoy, Ş; Özbakir, Ö; Yagbasan, A; Yücesoy, M | 1 |
| Chan, EW; Chen, L; Cheung, KS; Graham, DY; Leung, WK; Wong, AYS; Wong, ICK; Wong, IOL; Yeung, KF | 1 |
| Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G | 1 |
| Graham, DY; Hsu, PI; Kao, JY; Kao, SS; Kuo, CH; Lin, TF; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
| Allegretta, L; Baldassarre, G; Brandimarte, G; Cassieri, C; De Bastiani, R; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Licci, C; Miraglia, C; Penna, A; Picchio, M; Pranzo, G; Rizzo, GL; Savarino, E; Scida, S; Tursi, A | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L | 1 |
| Bair, MJ; Chang, CY; Chen, CC; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; Fang, YJ; Hsu, WF; Hu, WH; Kuo, CC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Twu, G; Wu, MS; Yang, TH; Yu, JJ | 1 |
| Chen, L; Chen, S; Chen, X; Chen, Y; Chu, H; Deng, Y; Ge, Q; He, H; He, J; Li, A; Long, Y; Wang, L | 1 |
| Baghbanian, M; Mirvakili, M; Salmanroghani, H; Salmanroghani, R; Sanati, G; Yazdian, P | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Chen, CL; Hsu, PI; Kao, JY; Kao, SS; Pan, CY; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
| Gan, HY; Huang, YM; Peng, TL; Su, KH; Yang, RJ; Yao, LY; Zhao, LL | 1 |
| Chen, S; Liu, D; Lu, H; Lv, N; Wang, J; Xie, Y; Zeng, Z; Zhang, L; Zhang, Z; Zhu, Z | 1 |
| Bazzoli, F; Conigliaro, R; Eusebi, LH; Farinati, F; Grande, G; Gravina, AG; Ierardi, E; Maconi, G; Panarese, A; Romano, M; Romiti, A; Savarino, E; Stasi, E; Zagari, RM | 1 |
| Karakan, T; Yalinay, M; Yildiz, SS | 1 |
| Fischbach, W; Malfertheiner, P | 1 |
| Dore, MP; Graham, DY; Lu, H | 2 |
| Cai, T; Tang, D; Wang, F; Yao, Y; Yuan, L; Yue, C | 1 |
| Chen, PY; Kuo, YT; Liou, JM; Wu, MS | 1 |
| Azmi, AN; Goh, KL; Graham, DY; Leow, AH; Loke, MF; Vadivelu, J | 1 |
| Bastón-Rey, I; Calviño-Suárez, C; de la Iglesia-García, D; Domínguez-Muñoz, JE; Macías-García, F; Nieto-García, L | 1 |
| Cai, Y; Dai, N; Du, Q; Hu, WL; Kao, JY; Kim, JJ; Si, JM; Zhang, YW; Zheng, WF | 1 |
| Heo, JJ; Jung, K; Kim, JH; Kim, SE; Moon, W; Park, MI; Park, SJ; Roh, JH | 1 |
| Chung, WC; Kim, YJ; Ko, SW; Lee, SJ | 1 |
| Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL | 1 |
| Kim, JM; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Soo In, C | 1 |
| Gao, CP; Han, SX; Wang, JX; Yang, X | 1 |
| Gisbert, JP; McNicholl, AG; Nyssen, OP | 1 |
| Chen, Y; Li, J; Liu, L; Lu, B; Wang, J | 1 |
| Fei, GJ; Guo, T; Li, JN; Li, XQ; Li, Y; Qian, JM; Shu, HJ; Wang, Q; Wu, X | 1 |
| Ji, C; Li, L; Li, Y; Liu, J; Sun, Y; Wang, T; Yang, X; Zuo, X | 1 |
| Alcedo, J; Alekseenko, S; Alonso-Galan, H; Barrio, J; Bordin, DS; Bujanda, L; Caldas, M; Coba, C; Dominguez-Jimenez, JL; Donday, MG; Fadeenko, G; Fernandez, MC; Gisbert, JP; Gonzalez-Cordero, PL; Hinojosa, J; Ilchishina, T; Lasala, JP; Lucendo, A; McNicholl, AG; Megraud, F; Modolell, I; Molina-Infante, J; Moreno, NF; Nuñez, O; Nyssen, OP; O'Morain, C; Perez-Aisa, Á; Ruiz-Zorrilla Lopez, R; Santaella, I; Sarsenbaeva, AS; Shvetz, O; Varela, P; Vologzhanina, L; Voynovan, I; Zakharova, NV; Zaytsev, O | 1 |
| Fallone, CA; Malfertheiner, P; Moss, SF | 1 |
| Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
| Bignon, E; Blin, P; Diquet, B; Droz-Perroteau, C; Guiard, E; Lassalle, R; Lelievre, B; Mégraud, F; Moore, N; Rouyer, M; Tison, F; Zerbib, F | 1 |
| Birkenfeld, S; Boltin, D; Dickman, R; Dotan, I; Gabay, H; Gingold-Belfer, R; Levi, Z; Niv, Y; Shochat, T | 1 |
| Graham, DY; Ji, Y; Liang, X; Long, X; Lu, H; Luo, L; Yu, L | 1 |
| Chen, Y; Gu, L; He, Y; Jiang, Y; Li, S; Liu, X; Peng, Y; Yang, H | 1 |
| He, C; Lu, N; Ouyang, Y; Peng, C; Shu, X; Wang, H; Zhu, Y; Zhu, Z | 1 |
| Acosta-Gonzales, G; Alsamman, MA; Moss, SF; Resnick, MB; Shawwa, K; Vecchio, EC | 1 |
| He, CX; Kong, FL; Kong, FT; Li, H; Liang, F; Liu, YL; Wang, KX; Zhao, W; Zhou, PP | 1 |
| Kılıç, ZMY; Özer Etik, D; Öztaş, E; Sezer, S; Suna, N | 1 |
| Graham, DY; Lu, H | 1 |
| Argueta, EA; Moss, SF | 1 |
| de Andrés, E; Gómez Hernando, C; Gómez Rodríguez, R; Muñoz Gómez, P; Sierra Bernal, C; Valle Muñoz, J | 1 |
| Fu, W; Song, Z; Zhou, L | 1 |
| Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M | 1 |
| Gholamrezaei, A; Hashemi, H; Khodadoostan, M; Minakari, M; Shavakhi, A; Shavakhi, S; Tabesh, E; Tabesh, F; Yaghoutkar, A | 1 |
| Andrews, PC; Busse, M; Ferrero, RL; Junk, PC; Trinh, I | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG | 1 |
| Graham, DY; Liang, X; Liao, J; Liu, W; Lu, H; Sun, Q; Xiao, S; Zhang, W; Zheng, Q | 1 |
| Graham, DY; Lee, YC; Wu, MS | 1 |
| Graham, DY; Lu, H; Zhang, W | 1 |
| Abbas, Z; Awan, S; Hamid, S; Jafri, F; Jafri, W; Naz, S; Usman, MW; Yakoob, J | 1 |
| Ecker, T; Krieger, T; Leandro, G; Malfertheiner, P; Venerito, M | 1 |
| Jang, JY; Jung, HK; Kim, CG; Kim, SG; Lee, H; Lee, HL; Lee, YC; Shin, ES; Shin, WG | 1 |
| Doğan, Z; Ergül, B; Filik, L; Sarikaya, M | 1 |
| Chen, A; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Shih, CA; Tsay, FW; Tseng, HH; Wang, HM; Wu, DC; Yu, HC | 1 |
| Ateş, Y; Avşar, E; Aytuğ, N; Bektaş, A; Bölükbaş, C; Dinçer, D; Ellidokuz, E; Erzin, Y; Güliter, S; Kaymakoğlu, S; Kocakaya, O; Onuk, MD; Poturoğlu, S; Taşan, G; Tiftikçi, A; Türkay, C; Yıldırım, B; Yılmaz, U | 1 |
| Bazzoli, F; Calvet, X; Fallone, C; Fischbach, L; Ford, AC; Forman, D; Gisbert, JP; Khan, KJ; Leontiadis, GI; Moayyedi, P; Oderda, G; Tse, F; Yuan, Y | 1 |
| Li, H; Sun, H; Xia, W | 1 |
| Graham, DY; Liou, JM; Wu, JY | 1 |
| Ang, TL; Song, M | 1 |
| Lee, SY | 1 |
| Chu, Y; Hu, F; Teng, G; Wang, S; Wang, W | 1 |
| Cheng, H; Gao, W; Hu, F; Zhang, X; Zhang, Y | 1 |
| Haider, RB; McNamara, D; O'Connor, H; O'Morain, C; Smith, SM | 1 |
| Chen, Y; Feng, W; Li, Q; Takase, M; Wu, X; Yang, L; Zhang, M; Zhao, T; Zhou, Z; Zhu, Y | 1 |
| Heo, J; Jeon, SW | 1 |
| Jo, HJ; Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L | 1 |
| Malfertheiner, P; Selgrad, M | 1 |
| Lv, ZF; Wang, B; Wang, H; Wang, YH; Xie, Y; Xiong, HF; Yang, Y | 1 |
| Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A | 1 |
| Algaba, A; Angueira, T; Barrio, J; Bermejo, F; Castro-Fernández, M; Del Castillo, F; Domínguez, JL; Federico, A; Fernández-Salazar, L; Gisbert, JP; Gómez, B; Gómez, J; Gravina, AG; Herranz, M; Lucendo, AJ; Marín, AC; Martorano, M; McNicholl, AG; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Pabón, M; Romano, M; Solís-Muñoz, P; Velayos, B | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L | 1 |
| Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
| Mahachai, V; Prapitpaiboon, H; Vilaichone, RK | 1 |
| Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
| Ahishali, E; Akkus, EE; Dabak, R; Dolapcioglu, C; Dolapcioglu, H; Kural, A; Sayiner, M | 1 |
| Bai, P; He, L; Li, Y; Lin, S; Qian, J; Song, Z; Wang, Y; Xue, Y; Zhang, J; Zhou, L | 1 |
| Ataseven, H; Baglıcakoglu, M; Biyik, M; Demir, A; Goktepe, H; Gungor, G; Kayacetin, E; Ucar, R | 1 |
| Gokcan, H; Onal, IK; Oztas, E | 1 |
| Annibale, B; Calabrese, C; Caselli, M; Di Mario, F; Farinati, F; Gasbarrini, G; Gullini, S; Ierardi, E; Luzza, F; Maconi, G; Ojetti, V; Pretolani, S; Romano, M; Rugge, M; Savio, A; Stockbrugger, R; Zagari, RM | 1 |
| Akhtar, N; Asif, HM; Sugiyama, T; Usmanghani, K; Zaidi, SF | 1 |
| Molina-Infante, J; Shiotani, A | 1 |
| Graham, DY; Lee, SY | 1 |
| Chaithongrat, S; Gamnarai, P; Mahachai, V; Namtanee, J; Prapitpaiboon, H; Vilaichone, RK; Wongcha-um, A | 1 |
| Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Andrews, PC; Blair, VL; Ferrero, RL; Junk, PC; Pathak, A; Tabor, RF | 1 |
| Birk, JW; Senatore, FJ; Wilmot, J | 1 |
| Jang, BI; Kim, KO; Kim, SB; Kim, TN; Lee, SH | 1 |
| Asilturk, Z; Basyigit, S; Hokkaomeroglu, M; Kefeli, A; Nazligul, Y; Sapmaz, F; Uzman, M; Yeniova, AO | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L; Tavani, R | 1 |
| Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
| Hwang, JC; Kang, JK; Kim, JH; Kim, SS; Lee, KM; Lim, SG; Park, RW; Shin, SJ; Yoon, D | 1 |
| An, HJ; Chen, Y; Cheng, H; Cui, M; Dong, L; Gao, H; Gao, W; Gong, J; Hu, F; Jiang, B; Jiang, K; Li, J; Li, Y; Liang, H; Meng, F; Sheng, J; Wang, B; Wang, H; Wei, H; Yang, L; Yang, Y; Zhang, G; Zhang, S; Zhao, P; Zhao, Y; Zuo, X | 1 |
| Arnold, CA; Coss, E; Cryer, B; Doern, CD; Dunbar, KB; Lam-Himlin, DM; Mitui, M; Okwara, C; Park, JY; Thung, I; Valasek, MA | 1 |
| Song, Z; Suo, B; Zhang, L; Zhou, L | 1 |
| Dore, MP; Graham, DY | 1 |
| Chiba, N; Fallone, CA; Fischbach, L; Gisbert, JP; Hunt, RH; Jones, NL; Leontiadis, GI; Marshall, JK; Moayyedi, P; Render, C; van Zanten, SV | 1 |
| Oberhofer, E | 1 |
| Marcus, EA; Sachs, G; Scott, DR | 1 |
| Amador, J; Bermejo, F; Bujanda, L; Calvet, X; Castro-Fernández, M; Cuadrado-Lavín, A; Elizalde, JI; Gene, E; Gisbert, JP; Gomollón, F; Lanas, Á; Martín de Argila, C; McNicholl, AG; Mearin, F; Molina-Infante, J; Montoro, M; Pérez-Aisa, Á; Pérez-Trallero, E | 1 |
| Amorena, E; Campillo, A; Kutz, M; La Iglesia, M; Ostiz, M | 1 |
| Fallone, CA; Shaikh, T | 1 |
| Baik, GH; Choi, SC; Hong, SJ; Jo, Y; Kim, GH; Kim, HJ; Kim, N; Kim, SE; Kim, WH; Lee, BE; Lee, JY; Oh, JH; Park, KS; Park, SM; Park, SY; Shim, KN | 1 |
| Bennison, J; Govan, L; Harbour, R; Manson, J; Watson, E; Wu, O; Xin, Y | 1 |
| Chen, Q; Fu, Q; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Atherton, J; Axon, AT; Bazzoli, F; El-Omar, EM; Gasbarrini, A; Gisbert, JP; Graham, DY; Hunt, R; Kuipers, EJ; Malfertheiner, P; Megraud, F; Moayyedi, P; O'Morain, CA; Rokkas, T; Rugge, M; Selgrad, M; Suerbaum, S; Sugano, K | 1 |
| Lin, JT; Liou, JM; Wu, MS | 1 |
| Chey, WD; Howden, CW; Leontiadis, GI; Moss, SF | 1 |
| Baldassarre, G; Boscariolo, L; De Bastiani, R; De Polo, M; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Grillo, S; Landi, S; Picchio, M; Tursi, A; Zamparella, M | 1 |
| Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X | 1 |
| Jung, K; Kim, HK; Kim, JH; Kim, SE; Lee, YD; Moon, W; Park, MI; Park, SJ | 1 |
| Ford, AC; Giguere, M; Khan, M; Malfertheiner, P; Moayyedi, P; Santana, J | 1 |
| Ran, ZH; Shen, J; Tong, JL; Xiao, SD | 1 |
| Cheng, H; Hu, FL | 1 |
| Akay, S; Akyildiz, M; Aydin, A; Musoglu, A; Tuncyurek, M | 1 |
| Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y | 1 |
| Derakhshan, F; Haghazali, M; Mirsattari, D; Mohsenian, N; Molaei, M; Talaie, R; Zali, MR; Zojaji, H | 1 |
| Kandulski, A; Malfertheiner, P; Selgrad, M | 1 |
| O'Connor, HJ; O'Morain, CA; Qasim, A; Saleem, A | 1 |
| Chey, WD; Higgins, PD; Luther, J; Moayyedi, P; Schoenfeld, PS; Vakil, N | 1 |
| Amini, M; Tajik, A | 1 |
| Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U | 1 |
| Vakil, N | 2 |
| Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N | 1 |
| Cheung, DY; Jung, HC; Jung, HY; Jung, SW; Song, HJ | 1 |
| Gökçe, S | 1 |
| Classen, M; Liu, W; Ma, J; Pan, K; Winawer, S; You, W; Zauber, A; Zhang, L; Zhao, H; Zhou, T | 1 |
| Andrews, PC; Ferrero, RL; Junk, PC; Kumar, I; Luu, Q; Nguyen, K; Taylor, JW | 1 |
| Baryshnikova, NV; Tkachenko, EI; Uspenskiĭ, IuP | 1 |
| BOBRANSKI, B; JANKOWSKI, J; WIERZCHOWSKI, J | 1 |
| Hwang, JH; Hwang, TJ; Jeong, SH; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Park, YS; Song, IS | 1 |
| Hibi, T; Nishizawa, T; Suzuki, H | 1 |
| Demir, M; Göktürk, S; Oztürk, NA; Serin, E; Yilmaz, U | 1 |
| Ceroni, L; Eusebi, LH; Fuccio, L; Kurelac, I; Laterza, L | 1 |
| Cai, M; Chen, Z; Hu, B; Huang, X; Huang, Y; Jiang, Y; Lin, H; Lu, L; Qu, X; Rong, L; Sun, D; Sun, X; Wu, L; Xiong, P; Yan, W; Zhong, L; Zhu, C | 1 |
| Kamysz, W; Kozlowski, H; Rowinska-Zyrek, M; Valensin, D; Witkowska, D | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Gao, XZ; Liu, F; Qiao, XL; Song, WC; Wang, XF | 1 |
| Chey, WD; Malfertheiner, P; Vakil, N | 1 |
| Malfertheiner, P | 4 |
| Gisbert, JP; McNamara, D; O'Connor, A; O'Morain, C | 1 |
| Fischbach, LA; Graham, DY | 1 |
| Chen, X; Li, MY; Liu, J; Wang, ZQ; Wu, C; Zhang, ZQ | 1 |
| Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S | 1 |
| Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A | 1 |
| Gao, W; Hu, FL; Wang, XM | 1 |
| Gisbert, JP | 1 |
| Astegiano, M; Cisarò, F; De Angelis, C; Pellicano, R; Rizzetto, M; Saracco, G | 1 |
| Li, CJ; Xu, MH; Zhang, GY | 1 |
| Choi, KD; Chung, JW; Jung, HY; Kim, JH; Lee, GH; Lee, JH; Oh, TH; Song, HJ; Yun, SC | 1 |
| Cuccu, M; Dore, MP; Farina, V; Graham, DY; Mameli, L; Massarelli, G | 1 |
| Chen, Z; Ge, R; Zhou, Q | 2 |
| Choi, JH; Hyun, JJ; Jung, SW; Kim, JH; Kim, SY; Koo, JS; Kwon, BS; Lee, SK; Lee, SW; Park, JY; Yim, HJ | 1 |
| Chuah, SK; Hsu, PI; Tsay, FW; Wu, DC | 1 |
| Bari, Z; Fakheri, H; Hosseini, V; Taghvaei, T | 1 |
| Anania, C; Chiesa, C; Olivero, E; Osborn, JF; Pacifico, L; Vaira, D | 1 |
| Inoue, H; Inoue, T; Maruoka, Y; Nakajima, S | 1 |
| Başer, O; Emer, O; Kadayifci, A; Kantarcioğlu, M; Kılcıler, G; Ozcan, A; Polat, Z; Uygun, A | 1 |
| Bari, Z; Fakheri, H; Sardarian, H | 1 |
| Agah, S; Ekhlasi, G; Ghourchian, S; Salehpour, A; Shidfar, F | 1 |
| Agarwal, A; Agrawal, GP; Agrawal, H; Jain, AK | 1 |
| Andrews, PC; Busse, M; Deacon, GB; Ferrero, RL; Junk, PC; MacLellan, JG; Vom, A | 1 |
| Buzás, GM | 1 |
| Cardenas, VM; Dominguez, DC; Graham, DY; Reddy, RK; Salazar, CO; Snyder, LK | 1 |
| Liang, X; Liu, W; Lu, H; Sun, Q; Xiao, S; Xu, X; Zhang, W; Zheng, Q | 1 |
| Wang, Y; Yu, Z; Zhang, S | 1 |
| Ammon, S; Klotz, U; Malfertheiner, P; Treiber, G | 1 |
| Bermejo, F; Boixeda, D; Defarges, V; García-Plaza, A; Hernández-Ranz, F; López-Sanromán, A; Martín-De-Argila, C; Milicua, JM | 1 |
| Cuena Boy, R | 1 |
| Michetti, P; Suerbaum, S | 1 |
| Coyle, W; Dunteman, T; Nemec, R; Sullivan, B | 1 |
| Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M | 1 |
| Chan, CK; Fung, FM; Ho, VY; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, GS; Wong, WM; Xia, HH; Yip, AW; Yuen, MF | 1 |
| Kullavanijaya, P; Tangkijvanich, P; Thong-Ngam, D; Treeprasertsuk, S; Wisedopas, N | 1 |
| Farup, PG; Høie, O; Lange, OJ; Tholfsen, J; Torp, R; Wetternus, S | 1 |
| Berstad, A; Hatlebakk, JG; Olafsson, S | 1 |
| Hopkins, RJ; Meyer, JM | 1 |
| Borody, T; Dallaire, C; De Boer, WA; Fallone, CA; Farley, A; Mégraud, F; O'Morain, C; Piotrowski, J; Schuman, R; Spénard, J; Tytgat, G | 1 |
| Chehter, EZ; Eisig, JN; Hashimoto, C; Laudanna, AA; Silva, FM | 1 |
| Azagra, R; Calvet, X; Gené, E; Gisbert, JP | 1 |
| Nurbaev, FE; Orziev, ZM; Rakhimova, GSh | 1 |
| Laine, L | 2 |
| Correa, P; Feldman, M; Fischbach, LA; Fontham, E; Goodman, KJ; Jain, R; Priest, E | 1 |
| Dore, MP; Graham, DY; Manca, A; Maragkoudakis, E; Marras, L; Nieddu, S; Realdi, G | 1 |
| Bästlein, E; Bayerdörffer, E; Haferland, C; Jacobs, E; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Papke, J; Schneider-Brachert, W; Stolte, M; Vieth, M | 1 |
| de Boer, SY; de Boer, WA; Siem, H; v d Meeberg, PC | 1 |
| Cammarota, G; Candelli, M; Carloni, E; Cazzato, IA; Cremonini, F; Di Caro, S; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Santarelli, L; Zocco, MA | 1 |
| Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
| Barkun, A; Chiba, N; Cockeram, A; Dallaire, C; Fallone, C; Farley, A; Nicholls, B; Simms, L; Veldhuyzen van Zanten, S | 1 |
| Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
| Balatsinou, C; Caldarella, MP; Cuccurullo, F; Di Bonaventura, G; Lapenna, D; Laterza, F; Milano, A; Neri, M; Piccolomini, R | 1 |
| Bianchi Porro, G; Cucino, C; Parente, F | 1 |
| Candelli, M; Franceschi, F; Gasbarrini, G; Mettimano, M; Migneco, A; Montebelli, R; Ojetti, V; Savi, L; Specchia, L | 1 |
| Berge, T; Berstad, A; Henriksen, TH; Lerang, F; Lia, A; Ragnhildstveit, E; Schøyen, R; Thoresen, T; Tveten, Y | 1 |
| de Boer, WA; Kuipers, EJ; Kusters, JG | 1 |
| Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
| Altintaş, E; Aydin, O; Camdeviren, H; Sezgin, O; Ulu, O | 1 |
| Calvet, X; Gené, E; Güell, M; Montserrat, A; Vergara, M | 1 |
| Choi, JH; Choung, RS; Chun, HJ; Han, WS; Hyun, JH; Jeen, YT; Jung, SW; Keum, B; Kim, CD; Kim, YS; Lee, HS; Lee, SW; Park, SC; Ryu, HS; Um, SH | 1 |
| de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ | 1 |
| Dickason, J; Fischbach, LA; van Zanten, S | 1 |
| De Francesco, V; Gatta, L; Hassan, C; Ierardi, E; Morini, S; Panella, C; Vaira, D; Zullo, A | 1 |
| Candelli, M; Carloni, E; Cazzato, A; Di Campli, C; Fini, L; Gasbarrini, A; Gasbarrini, G; Nista, EC; Pignataro, G; Zocco, MA | 1 |
| Cheon, JH; Hwang, JH; Jung, HC; Kim, JM; Kim, JW; Kim, N; Lee, DH; Park, YS; Song, IS; Suh, SO | 1 |
| Filik, L; Köksal, AS; Odemiş, B; Ozden, A; Parlak, E; Sahin, B; Saşmaz, N; Ulker, A; Yolcu, OF | 1 |
| Shao, Y; Wang, YS; Yang, H; Yu, ZL; Zhang, L; Zhang, ST | 1 |
| Calvet, X; Carpio, D; Fuentes, J; Gisbert, JP; Guardiola, J; Olivares, D; Tito, L; Tomas, A | 1 |
| Huang, JQ; Hunt, RH; Karlberg, J; Lam, SK; Wong, BC; Wong, WM; Zheng, GF | 1 |
| Calvet, X; Gisbert, JP; Gonzalez, L | 1 |
| Shao, Y; Yu, ZL; Zhang, L; Zhang, ST | 1 |
| Almeida, JR; Campos, LT; Guerrazzi, F; Lorena, SL; Mesquita, MA; Montes, CG; Zeitune, JM | 1 |
| Aeed, H; Avni, Y; Birkenfeld, S; Eliakim, R; Levine, A; Shabat-Sehayek, V; Shevah, O; Shirin, H; Wardi, J | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Lee, JH; Park, MJ; Song, IS | 1 |
| Gisbert, JP; Pajares, JM | 2 |
| Aumais, C; Brunet, JS; Grace, M; Lefebvre, M; Massicotte, J; Spénard, J; Tremblay, C | 1 |
| Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
| Borody, TJ | 2 |
| Fukuda, Y; Sakagami, T | 1 |
| Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
| Gisbert, JP; Morena, F | 1 |
| Azuma, T; Ishibashi, M; Migita, K; Mikata, Y; Miyoshi, Y; Murafuji, T; Rahman, AF; Sugihara, Y | 1 |
| Donovan, JL; Egger, M; Harvey, IM; Harvey, RF; Lane, JA; Murray, LJ; Nair, P; Noble, S | 1 |
| Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A | 1 |
| Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P | 1 |
| Akarca, US; Aydin, A; Musoğlu, A; Onder, GF; Tekin, F; Tunçyürek, M | 1 |
| Kerton, A; Warden, P | 1 |
| Lule, GN | 1 |
| Lee, KH; Tam, YH; Yeung, CK | 1 |
| Altintaş, E; Sezgin, O; Tataroğlu, C; Uçbilek, E | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Kim, SG; Lee, DH; Song, IS | 1 |
| Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P | 1 |
| Hausinger, RP; Ko, BB; Leung, AF; Mulrooney, SB; Sun, H; Zeng, Y; Zhang, L | 1 |
| Buzás, GM; Józan, J | 2 |
| Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR | 1 |
| Bair, MJ; Chang, WH; Ke, HL; Kuo, FC; Lu, CY; Wang, SW; Wang, TE; Wang, YY; Wu, DC; Wu, IC; Yuan, SS | 1 |
| Choe, YH; Choi, J; Jang, JY; Kim, JS; Kim, KM; Park, HY | 1 |
| Gisbert, JL; Gisbert, JP; Marcos, S; Moreno-Otero, R; Pajares, JM | 1 |
| Arvanitakis, SN; Ashorn, M; Bontems, P; Cadranel, S; Canani, RB; Casswall, T; Celinska-Cedro, D; De Giacomo, C; Drumm, B; Gandullia, P; Gómez, MJ; Gottrand, F; Kalach, N; Oderda, G; Pehlivanoglu, E; Ravelli, A; Roggero, P; Roma, E; Romano, C; Rutigliano, V; Shcherbakov, P; Urruzuno, P | 1 |
| Aiello, F; Brandimarte, G; Elisei, W; Giorgetti, GM; Modeo, ME; Tursi, A | 1 |
| Kadayifçi, A | 1 |
| Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P | 1 |
| Mahachai, V; Thong-Ngam, D | 1 |
| Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A | 1 |
| Bravo, JC; Bravo, LE; Camargo, MC; Ceron, C; Correa, P; Delgado, AG; Fontham, ET; Mera, RM; Piazuelo, MB; Yepez, MC | 1 |
| Buzás, GM; Széles, I | 1 |
| Cun, S; Ge, R; Li, H; Lin, MC; Sun, H | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Baker, DE | 1 |
| Anver, MR; Battles, JK; Blumenauer, LL; Gonda, MA; Gorelick, PL; Haines, DC; Russell, RJ; Ward, JM | 1 |
| Alvarez Baleriola, I; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Vila, T | 1 |
| Alvarez Baleriola, I; Bermejo, F; Boixeda, D; de Rafael, L; García Plaza, A; Gisbert, JP; Martín de Argila, C | 1 |
| Becker, T; Börsch, G; Köhl, H; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B | 1 |
| Dettmer, A; Domschke, W; Fenner, T; Gregor, M; Hesse, P; Holtmann, G; Miederer, SE; Schentke, KU; Schütz, E; van Husen, N | 1 |
| Wilson, WH | 1 |
| Jablonská, M | 1 |
| Contreras, L; Giglio, M; Hoffenberg, P; Ossa, P; Reyes, V; Weitz, JC | 1 |
| Folwaczny, C | 1 |
| Foltz, CJ; Fox, JG; Shames, B; Yan, L | 2 |
| Kim, EC; Seo, JK; Sim, JG | 1 |
| Forman, D; Harwood, D; Logan, RP; Milne, R; Misiewicz, JJ | 1 |
| Bour, LJ; Eekhof, JL; Noach, LA; Ongerboer de Visser, BW; Posthumus Meyjes, FE; Tytgat, GN | 1 |
| Talley, NJ | 3 |
| Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Nesje, LB; Wilhelmsen, I | 1 |
| Golochevskaia, VS; Grebenev, AL; Lapina, TL; Miagkova, LP; Sklianskaia, OA | 1 |
| Appelman, HD; Barnett, JL; Behler, EM; Crause, I; Elta, GH; Nostrant, TT; Scheiman, JM | 1 |
| Asnicar, MA; Chong, SK; Croffie, JM; Fitzgerald, JF; Lee, CH; Lou, Q; Zimmerman, SE | 1 |
| de Boer, WA; Tytgat, GN | 2 |
| Fennerty, MB | 2 |
| Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX | 1 |
| Ciociola, AA; Goodwin, BB; Perschy, TB; Webb, DD | 1 |
| Blecker, U; Hart, J; Kirschner, BS; McKeithan, TW | 1 |
| Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S | 1 |
| Cheng, AF; Chung, SC; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ | 1 |
| Peterson, WL; Walsh, JH | 1 |
| de Graaf, B; Thijs, JC; van Zwet, AA | 1 |
| Barnes, J | 1 |
| Börsch, G; Labenz, J | 3 |
| Coll, I; Espinós, JC; Forné, M; Garau, J; Tresserra, F; Viver, JM | 1 |
| O'Connor, HJ | 2 |
| Cohen, MH | 1 |
| Clyne, M; Daly, LE; Drumm, B; Durnin, MT; Gormally, SM; Kierce, BM; Prakash, N | 1 |
| Müller, P; Simon, B | 2 |
| Burette, A; Glupczynski, Y | 2 |
| Bajador, E; Gomollón, F | 1 |
| Klotz, O; Treiber, G | 1 |
| Coudron, PE; Stratton, CW | 2 |
| Harvey, I; Murray, L | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| de Boer, WA; Driessen, WM | 1 |
| Berstad, A; Wilhelmsen, I | 1 |
| Rune, SJ | 1 |
| Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K | 1 |
| al-Assi, MT; Cole, RA; Genta, RM; Graham, DY; Karttunen, TJ | 1 |
| Giannikos, N; Kalogeropoulos, N; Karameris, A; Mavrogeorgis, A; Papatheodorou, G; Rokkas, T | 1 |
| Berndt, H | 1 |
| Banerjee, S; el-Omar, E; McColl, KE | 1 |
| Dhillon, AP; Fraser, AG; Pounder, RE; Sankey, EA; Sim, R | 1 |
| Marshall, BJ | 3 |
| Bertrams, J; Börsch, G; Labenz, J; Rühl, GH | 1 |
| Noach, LA; Reijers, MH; Tytgat, GN | 1 |
| Lee, WY; Lin, JT; Wang, JT; Wang, TH; Wu, MS; Yang, JC | 1 |
| Asaka, M; Horita, S; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Ohtaki, T | 1 |
| Lamouliatte, H | 1 |
| Gad, A; Unge, P | 1 |
| Schütz, E; Stolte, M | 1 |
| Andersen, L; Krasilnikoff, PA; Wewer, V | 1 |
| Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hjartholm, AS; Hundal, O; Nesje, LB; Nysaeter, G; Wilhelmsen, I | 1 |
| de Boer, WA; Driessen, WM; Potters, VP; Tytgat, GN | 1 |
| Azian, M; Chuah, SY; Goh, KL; Lo, YL; Ong, KK; Parasakthi, N; Peh, SC; Wong, NW | 1 |
| Hentschel, E | 1 |
| Cuccurullo, F; Di Iorio, P; Laterza, F; Mezzetti, A; Neri, M; Seccia, G; Susi, D | 1 |
| Campbell, DR; Cherian, R; McGregor, DH; Weston, AP | 1 |
| Berstad, A; Berstad, K; Sjödahl, R | 1 |
| Dent, J; Eyre-Brook, IA; Lobo, AJ; McNulty, CA; Uff, JS; Wilkinson, SP | 1 |
| al-Assi, MT; Genta, RM; Graham, DY | 1 |
| Graham, DY; Peura, DA | 1 |
| al-Assi, MT; Genta, RM; Graham, DY; Lew, GM; Ramirez, FC | 1 |
| Bleck, J; Gebel, M; Gladziwa, U; Haruma, K; Manns, M; Schmidt, H; Soudah, B; Wagner, S | 1 |
| Boixeda, D | 1 |
| Martínez, MJ | 1 |
| Corinaldesi, R; De Giorgio, R; Gasperoni, S; Paparo, GF; Poli, L; Stanghellini, V; Tucci, A; Varoli, O | 1 |
| Reilly, TG; Walt, RP | 1 |
| Chang, FY; Chen, TS; Lee, SD; Tsay, SH | 1 |
| Berman, D; George, J; Groisman, GM; Harpaz, N | 1 |
| McGuffey, EC | 1 |
| Correa, P; Fontham, ET; Hunter, FM; Johnson, WD; Malcom, GT; Rood, JC; Ruiz, B; Sobhan, M | 1 |
| Beglinger, C | 1 |
| Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I | 1 |
| Berstad, A; Berstad, K | 1 |
| Brazer, SR; Maniatis, AG | 1 |
| Genta, RM; Go, MF; Graham, DY; Lew, GM; Rehfeld, JF | 1 |
| Graham, DY; Hazell, SL; Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Correa, P; Fontham, E; Hunter, FM; Ruiz, B; Samloff, IM; Sobhan, M | 1 |
| Hammar, CH; Jaspersen, D | 1 |
| Aoyama, N; Morimoto, S; Nakashima, T; Ohmoto, A | 1 |
| Kihira, K; Kimura, K; Sato, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA | 1 |
| Gottrand, F; Husson, MO; Leclerc, H; Turck, D | 1 |
| Nasu, M | 1 |
| Hassall, E; Israel, DM | 1 |
| Börsch, G; Gyenes, E; Labenz, J; Rühl, GH | 2 |
| Andrews, P; Borody, TJ; Carroll, M; Ferch, N; Jankiewicz, E | 1 |
| Calam, J; Moss, SF | 1 |
| Cohen, H; Dooley, CP; Field, LG; Frierson, HF; Guerrant, RL; Jerdack, GR; Marshall, BJ; McCallum, RW; Mitra, S; Valenzuela, JE | 1 |
| Asaka, M; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Miyazaki, T | 1 |
| Fedotin, MS | 1 |
| Cutler, AF; Schubert, TT | 2 |
| Campbell, CJ; Clayton, NM; Clitherow, JW; Grinham, CJ; McColm, AA; McLaren, A; Stables, R; Trevethick, MA | 1 |
| Axon, AT | 2 |
| Della Casa, G; Di Gregorio, C; Ferrari, AM; Frazzoni, M; Grisendi, A; Lonardo, A; Melini, L; Pulvirenti, M | 1 |
| Aimo, G; Bonesi, R; Pistoso, S; Piubello, W; Raggi, G; Soldinger, E; Superti, G; Vitali, E | 1 |
| Bagshaw, JA; McColm, AA; O'Malley, CF | 1 |
| Kanayama, S; Matsuzawa, Y; Nakanishi, T; Shinomura, Y | 1 |
| Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Ramirez, FC | 1 |
| Glassman, MS; Halata, MS; Rosioru, C; Schwarz, SM | 1 |
| Jaskiewicz, K; Louw, JA; Marks, IN | 1 |
| Ramírez Ramos, A | 1 |
| Boixeda, D; Gisbert, JP; Martín de Argila, C; Monés, J; Mur Villacampa, M; Sáinz Samitier, R | 1 |
| Boixeda, D; Gisbert, JP; Hernández Ranz, F; Martín de Argila, C | 1 |
| Harris, AW; Misiewicz, JJ | 1 |
| Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M | 1 |
| Bardhan, KD; Dekkers, CP; Forster, JK; Kler, L; Lacey, LF; Lam, SK; Nowak, A; Schaffalitzky de Muckadell, OB; Schutze, K; Tildesley, G | 1 |
| Bästlein, E; Bayerdörffer, E; Heldwein, W; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Müller-Lissner, S; Sommer, A; Weingart, J | 1 |
| Soll, AH | 1 |
| Fennerty, MB; Vakil, N | 1 |
| Treiber, G | 1 |
| Davis, S | 1 |
| Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hundal, O; Nesje, LB; Nysaeter, G; Olafsson, S; Tefera, S | 1 |
| Laine, LA | 1 |
| Alvarez Baleriola, I; Boixeda, D; de Rafael, L; García Plaza, A; García, M; Gisbert, JP; Martín de Argila, C | 1 |
| Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J | 1 |
| Alkan, S; Cohen, P; Karcher, DS; Newman, MA | 1 |
| Keller, JJ; Rauws, EA; Tytgat, GN; van der Hulst, RW | 2 |
| Coyle, W; Dresner, D; Duntemann, T; Lawson, JM; Nemec, R; Peterson, R | 1 |
| Tytgat, GN | 2 |
| Unge, P | 2 |
| Axon, AT; Moayyedi, P | 1 |
| Jönsson, B | 1 |
| Bell, GD; Powell, KU | 1 |
| Satoh, K | 1 |
| Caucheteur, B; De Koster, E; Deltenre, M; Jonas, C; Otero, J | 1 |
| Bermejo, F; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Redondo, C | 1 |
| Arnold, R; Bayerdörffer, E; Behrens, R; Birkner, B; Braden, B; Caspary, WF; Domschke, W; Koletzko, S; Labenz, J; Malfertheiner, P; Menge, H; Rösch, W; Schepp, W; Stolte, M; Strauch, M | 1 |
| de Boer, WA | 3 |
| Bergseth, M; Berstad, A; Berstad, K; Hundal, O; Olafsson, S; Tefera, S; Wilhelmsen, I | 1 |
| Gabryelewicz, A | 1 |
| Bästlein, E; Bayerdörffer, E; Bolle, KH; Hatz, R; Heldwein, W; Höchter, W; Klann, H; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Ruckdeschel, G; Simon, T; Sommer, A; Stolte, M; Weingart, J | 1 |
| de Boer, WA; Driessen, WM; Jansz, AR; Tytgat, GN | 1 |
| Ciociola, AA; McSorley, DJ; Peterson, WL; Sykes, DL; Webb, DD | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ | 1 |
| Cilleruelo Pascual, ML; Echávarri Olavarría, F; Manzanares López-Manzanares, J; Medina Benítez, E; Molina Arias, M; Román Riechman, E; Urruzuno Tellería, P | 1 |
| De Boer, WA; Driessen, WM; Tytgat, GN | 1 |
| Geypens, B; Ghoos, Y; Hiele, M; Maes, B; Perri, F; Rutgeerts, P | 1 |
| Webb, DD | 1 |
| Dammann, HG | 1 |
| Bardhan, KD; Buckley, MJ; De Koster, EH; Duggan, AE; Gilvarry, J; Gummett, PA; Logan, RP; O'Morain, CA; Pounder, RE; Rauws, EA; Schaufelberger, HD; Wyeth, JW | 1 |
| De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY | 1 |
| Hackelsberger, A; Malfertheiner, P | 1 |
| Beastall, G; Beattie, AD; Morton, R; Park, RH; Taha, AS | 1 |
| Behler, EM; Chey, WD; Crause, I; Elta, GH; Scheiman, JM | 1 |
| Bonagura, AF; Dabezies, MA | 1 |
| Daróczy, J; Ferenczi, K; Kalas, D; Pálos, G; Prónai, L | 1 |
| Bardhan, KD | 1 |
| Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Ciociola, AA; Heath, A; Walsh, JH; Webb, DD | 1 |
| Goddard, AF; Spiller, RC | 1 |
| Harris, A; Misiewicz, JJ | 2 |
| Lux, G | 1 |
| Bästlein, E; Bayerdörffer, E; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Stolte, M | 1 |
| Goh, KL; Navaratnam, P; Peh, SC | 1 |
| Carmichael, JM; Patchin, GM; Wieland, KA | 1 |
| Freston, JW; Murphy, K; Taylor, JL; Zagari, M | 1 |
| Goodwin, CS; Mendall, MM; Northfield, TC | 1 |
| Axon, AT; Ireland, A; Rooprams, PD; Smith, MJ | 1 |
| Scott, BB; Vautier, G | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ | 1 |
| Seifrit, B | 1 |
| Choi, CH; Chung, EC; Kung, NN; Kwok, SP; Li, TH; Lim, BH; Ma, HC; Ng, PW; Sung, JJ; Wong, KC; Yuen, NW | 1 |
| Chan, FK; Chan, LY; Chung, SC; Lee, YT; Leung, WK; Sung, JJ; Yung, MY | 1 |
| Biasco, G; Paparo, GF; Tucci, A | 1 |
| Blecker, U; Gold, BD | 1 |
| Agrawal, BK; Dayal, VM; Kamal, J; Kumar, P; Shahi, SK | 1 |
| Hunt, RH | 1 |
| Aubert, E; Berge, T; Efskind, PS; Haug, JB; Hauge, T; Henriksen, M; Lerang, F; Moum, B; Nicolaysen, K; Odegaard, A; Ragnhildstveit, E; Søberg, T; Tolås, P | 1 |
| Peterson, WL | 1 |
| Lambert, JR; Midolo, P | 1 |
| Pounder, RE; Williams, MP | 1 |
| Drumm, B; Durnin, M; Goggin, N; Moriarty, S; Rowland, M; Walsh, D | 1 |
| Damianos, AJ; McGarrity, TJ | 1 |
| Forbes, GM | 1 |
| Fock, KM | 1 |
| Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K | 1 |
| Beattie, S; Buckley, MJ; Gilvarry, J; Hamilton, H; O'Morain, CA | 1 |
| Angeletti, S; Annibale, B; Bordi, C; Delle Fave, G; Malagnino, F; Mancino, C; Marignani, M | 1 |
| Pounder, RE | 1 |
| Kim, MJ; Michener, R; Triadafilopoulos, G | 1 |
| Angel, A; Genta, RM; Graham, DY; Gutiérrez, O; Otero, W; Segura, AM | 1 |
| Hoffman, JS | 1 |
| Myers, D | 1 |
| Hogan, J; Krasner, N; Lombard, M; Purkayastha, SK; Tan, WC | 1 |
| Bardhan, KD; Dallaire, C; Duggan, AE; Eisold, H | 1 |
| Bisso, G; Caroli, M; Celle, G; Mansi, C; Mela, GS; Mele, MR; Olivieri, A; Saggioro, A; Savarino, V; Termini, R; Tosatto, R; Vigneri, S | 1 |
| Hamilton, MR; Pounder, RE; Sercombe, JC; Williams, MP | 1 |
| Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM | 1 |
| Chan, CS; Chan, FK; Chung, SC; Lee, YT; Leung, VK; Li, EK; Sung, JJ; To, KF; Woo, J; Yung, MY | 1 |
| Abdel-Rahman, SM; Nahata, MC; Robinson, DM | 1 |
| El-Zaatari, F; Engstrand, L; Genta, RM; Graham, D; Scheynius, A | 1 |
| el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M | 1 |
| Cervantes Bustamante, R; Cuevas, S; Mata Rivera, N; Oyervides Garcia, I; Ramirez Mayans, JA; Zamora Davila, E; Zarate Mondragón, FE | 1 |
| Eaton, KA; Kramer, LW; Wack, RF | 1 |
| Malfertheiner, P; Mégraud, F | 1 |
| Batchelder, M; Fox, JG; Hayward, A; Murphy, JC; Palley, L; Shames, B; Yan, L | 1 |
| Bierman, JC; Blanchard, TG; Czinn, SJ; Diters, RW; Leunk, RD | 1 |
| Cheng, AF; Chung, SS; Ling, TK; Sung, JJ; Yiu, PY | 1 |
| Emami, S; Estrada, R; Laine, L; Trujillo, M | 1 |
| Minocha, A; Srinivasan, R | 1 |
| Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J | 1 |
| Bielański, W; Bobrzyński, A; Budzyński, A; Gedliczka, O; Konturek, S; Stachura, J | 2 |
| Bolin, TD; Engelman, JL; Korman, MG; Pianko, S | 1 |
| Bazzoli, F; Pozzato, P | 1 |
| Dixon, JS; Mills, JG; Pipkin, GA; Wood, JR | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lau, JY; Lee, YT; Leung, VK; Leung, WK; Ling, TK; Ng, EK; Suen, R; Sung, JJ | 1 |
| Berge, T; Haug, JB; Henriksen, M; Lerang, F; Moum, B; Ragnhildstveit, E; Sandvei, PK; Tolås, P; Whist, JE | 1 |
| Drumm, B; Walsh, D | 1 |
| Parsonnet, J | 1 |
| Berg, DE; Blaser, MJ; Dubois, A; Fiala, N; Heman-Ackah, LM; Perez-Perez, GI | 1 |
| Dibrova, IuA; Gomoliako, IV; Grigorova, IV; Saenko, VF; Shmatko, VI | 1 |
| Pipkin, GA; Williamson, R; Wood, JR | 2 |
| Bardhan, KD; Jahnsen, J; Lotay, N; Marcelino, M; Roberts, PM; Wurzer, H | 1 |
| Ariano, RE; Tkach, CL | 1 |
| Scott, BB | 1 |
| De Wolff, FA; Noach, LA; Slikkerveer, A; Tytgat, GN; Van der Voet, GB | 1 |
| Ducóns, JA; Fuentes, J; García, S; Gimeno, L; Gomollón, F; Montoro, M; Vera, J | 1 |
| Battaglia, G; Benvenuti, ME; Del Bò, N; Di Mario, F; Donisi, PM; Leandro, G; Pasini, M; Pasquino, M; Vianello, F; Vigneri, S | 1 |
| Calvet Calvo, X | 1 |
| Vondracek, TG | 1 |
| Breslin, NP; O'Morain, C | 1 |
| Bardhan, KD; Blakemore, CB; Cary, BA; Hinchliffe, RF; Morris, P; Singh, S; Thompson, M; Wall, RM | 1 |
| Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E | 1 |
| Brullet, E; Calvet, X; Campo, R; Comet, R; García, N; Navarro, M | 1 |
| Ara, JR; Bertol, V; Brieva, L; Canellas, A; del Agua, C | 1 |
| Bazzoli, F; Cardelli, A; Catalano, FA; Giglio, A; Lami, F; Olivieri, A; Pilotto, A; Pozzato, P; Roda, E; Scarpulla, G; Spadaccini, A; Susi, D; Tosatto, R; Zagari, M | 1 |
| Crobach, LF; Geraedts, AA; Kolkman, JJ; Nicolai, JJ; Oudkerk Pool, M; Tan, TG; Timmerman, RJ; Van Der Laan, J; Van Kleef, WA; Wolff, AA | 1 |
| de Boer, WA; Haeck, PW; Mulder, CJ; Otten, MH | 1 |
| Ahsan, K; Hadjiyane, C; Karakurum, A; Mohammed, I; Nawaz, A; Pellecchia, C | 1 |
| Fendrick, AM; Jeffries, MA; Scheiman, JM | 1 |
| Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianei, R; Cuoco, L; Fedeli, G; Fedeli, P; Gasbarrini, A; Gasbarrini, G; Papa, A; Tursi, A | 1 |
| Carvalho, AF; Da Silva, CM; De Nucci, G; Ferraz, JG; Fiorelli, LA; Jorge, VN; Pedrazzoli, J | 1 |
| Bashirova, ES; Butorov, IL; Darvin, VV; Lokhvitskiĭ, SV; Proshin, AV | 1 |
| Kleibeuker, JH; Kooy, A; Thijs, JC; van der Wouden, EJ; van Zwet, AA | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY | 1 |
| Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB | 1 |
| Ciociola, AA; Heath, A; Lanza, FL; McSorley, DJ; Sontag, SJ; Sykes, DL | 1 |
| Funch-Jensen, P; Hallas, J; Juul, KV; Kolmos, HJ; Lauritsen, K; Nissen, A; Thomsen, OO | 1 |
| Oderda, G | 1 |
| Malfertheiner, P; Menegatti, M; Peitz, U; Vaira, D | 1 |
| Howden, CW; Hunt, RH | 1 |
| Bardhan, KD; Duggan, AE; Gudjonsson, H; Hoie, O; Kliebe-Frisch, C; Kristensen, ES; Pipkin, GA; Schuetz, E | 1 |
| Bellin, EY; Fletcher, DD; Shuter, J; Simone, VJ | 1 |
| Barnett, J; Chey, WD; Delvalle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Palaniappan, J; Scheiman, J | 1 |
| Chang, MH; Hsu, HY; Huang, FC; Lee, PI; Shun, CT | 1 |
| Biagini, R; Bilardi, C; Bisso, G; Celle, G; Mansi, C; Mele, MR; Pivari, M; Savarino, V; Termini, R; Vigneri, S; Zentilin, P | 1 |
| Eshraghi, J; Fassihi, R; Yang, L | 1 |
| Dial, EJ; Fox, JG; Lechago, J; Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Fukuda, Y; Shimoyama, T; Yamamoto, I | 1 |
| Aoyama, N; Sakai, T; Shirakawa, K; Shirasaka, D | 1 |
| DiBaise, JK; Dy, RM; Lof, J; Quigley, EM | 1 |
| Ozbakir, O; Turasan, A; Utaş, C; Utaş, S | 1 |
| Anti, M; Armuzzi, A; Bianchi Porro, G; Cammarota, G; Deltenre, M; Franceschi, F; Gasbarrini, A; Gasbarrini, G; Malfertheiner, P; Mégraud, F; O'Morain, C; Pajares-García, J; Pretolani, S; Quina, M | 1 |
| Choi, CH; Kung, NN; Lai, WM; Lam, KN; Leung, EM; Li, TH; Lui, YH; Ng, PW; Sung, JJ; Yuen, NW | 1 |
| Kabala, A; Pawłowski, W; Petsch, B | 1 |
| Attili, AF; De Francesco, V; Faleo, D; Hassan, C; Rinaldi, V; Stoppino, V; Winn, S; Zullo, A | 1 |
| Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Osato, MS; Qureshi, W | 1 |
| Kleibeuker, JH; Kooy, A; Thijs, JC; Van der Wouden, EJ; Zwet, AA | 1 |
| Fennerty, MB; Kelly, C; Knigge, K; Peterson, WL | 1 |
| Marshall, JB | 1 |
| Aasen, AJ; Berdal, BP; Bergan, T; Dahlgren, A; Gammelsaether, M; Gløgård, C; Klaveness, J | 1 |
| Blanchard, J; Boden, J; Ermak, T; Georgakopoulos, K; Giannasca, P; Gray, H; Hill, J; Ingrassia, J; Kleanthous, H; Lee, CK; Monath, TP; Soike, K; Tibbitts, T; Weltzin, R | 1 |
| Ashktorab, H; Hinds, T; Jagtap, J; Kim, KS; Scott, VF; Smoot, DT | 1 |
| Cave, DR; Hoffman, JS; Katz, LM | 1 |
| Buring, SM; Doering, PL; Hatton, RC; Winner, LH | 1 |
| Hirschowitz, BI; Mönkemüller, KE | 1 |
| Cutler, A; Vakil, N | 1 |
| Anderson, SY; Graham, DY; Lang, T | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R | 1 |
| Gisbert, JP; Pajares, JM; Valle, J | 1 |
| Yao, X | 1 |
| McSorley, DJ; Perschy, TB; Schwartz, HI; Sorrells, SC | 1 |
| Choe, YH; Hong, YC; Kim, SK; Lee, DH; Pai, SH; Son, BK | 1 |
| Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H | 1 |
| Jansen, JB; Laheij, RJ; Rossum, LG; Straatman, H; Verbeek, AL | 1 |
| Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
| Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Berstad, A; Hatlebakk, JG; Tefera, S | 1 |
| Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
| Neiger, R; Schmassmann, A; Seiler, G | 1 |
| Cabanillas, FF; Ford, R; Genta, RM; Glober, G; Graham, DY; Hagemeister, FB; Johnson, CM; Lahoti, S; Lee, JE; Luthra, R; Lynch, PM; Manning, JT; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sample, D; Sarris, AH; Shen, Y; Steinbach, G; Winn, RJ; Younes, A | 1 |
| Dashti, M; Massarrat, S; Pahlewanzadeh, MR; Roghani, HS | 1 |
| Bardhan, KD; Farley, A; French, PC; Paré, P; Roberts, PM; Romãozinho, JM | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Suen, R; Sung, JJ; Wu, JC | 1 |
| Chippendale, GR; Garner, RM; Gilbert, JV; Kane, AV; Mobley, HL; Plaut, AG | 1 |
| Bravo, LE; Campo, C; Correa, P; Mera, R; Realpe, JL | 1 |
| Axon, A | 1 |
| Angeles Arpa, M; Bermejo, F; Boixeda, D; García Arata, I; García Plaza, A; Gisbert, JP; Jesús Higes, M; Martín de Argila, C; Nieves Rincón, M | 1 |
| Coyle, WJ; Duntemann, T; Lawson, JM; Murphy, M; Nemec, R; Peterson, R; Sedlack, RE | 1 |
| Dagalp, K; Kadayifci, A; Kilinc, R; Uygun, A | 1 |
| Berstad, A; Olafsson, S | 1 |
| Carpio, D; Gisbert, JL; Gisbert, JP; Grávalos, RG; Marcos, S; Pajares, JM | 1 |
| Canning, A; Egan, C; Farraye, FA; Kemp, JA; Lee, M; Tataronis, G | 1 |
| Mach, T; Zahradnik-Bilska, J | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y | 1 |
| Dubois, A; Heman-Ackah, LM; Mysore, JV; Simon, PM; Wigginton, T; Zopf, D | 1 |
| Borda, F; Domínguez, E; Gisbert, JP; Sainz, R | 1 |
| Alonso García, I; García Pérez, A; Giménez Samper, M; Valverde de La Osa, J | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Papa, A; Pastorelli, A | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Gentiloni, N; Ojetti, V; Pastorelli, A; Pirozzi, G | 1 |
| Anti, M; Armuzzi, A; Branca, G; Candelli, M; Canducci, F; Fadda, G; Fedeli, G; Gasbarrini, A; Gasbarrini, G; Ojetti, V; Pastorelli, A; Pola, P; Torre, ES | 1 |
| De Boer, WA; Jansen, JB; Schneeberger, PM; Van De Wouw, BA; Van Etten, RJ; Van Oijen, AH | 1 |
| Chan, FK; Chung, SC; Ling, TK; Suen, R; Sung, JJ; Wu, JC | 1 |
| Chey, WD; Chien, NN; Chung, NQ; Connor, BA; Henley, KS; Hoan, PQ; Hop, TV; Lak, BV; Long, T; Mao, HV; Perez-Perez, GI; Stone, CD; Thang, DM | 1 |
| Gurer, I; Hilmioglu, F; Ozyilkan, E; Sare, M; Taskin, V | 1 |
| Bravo, JC; Bravo, LE; Correa, P; Realpe, JL; Ruiz, B; van Doorn, LJ | 1 |
| Brousal, A; Kearney, DJ | 1 |
| Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R | 1 |
| Barkun, AN; Beech, R; Best, L; Fallone, CA; Friedman, G; Joseph, L; Loo, V; Mayrand, S | 1 |
| Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG | 1 |
| Bisson, S; Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD | 1 |
| Fox, JG; Marini, RP; McColm, AA; Taylor, NS; Williamson, R; Yan, L | 1 |
| Sung, JJ | 1 |
| Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Opekun, AR; Osato, MS | 1 |
| Fairman, KA; Motheral, BR | 1 |
| Chmiela, M; Czkwianianc, E; Lawnik, M; Płaneta-Małecka, I; Rudnicka, W | 1 |
| Bilardi, C; Bisso, G; Borgonovo, G; Borro, P; De Salvo, L; Dulbecco, P; Mansi, C; Pivari, M; Raffaella Mele, M; Savarino, V; Tessieri, L; Vigneri, S; Zentilin, P | 1 |
| De Boer, WA; Jansen, JB; Van Oijen, AH; Verbeek, AL | 1 |
| Castellote, J; Porta, F | 1 |
| Calvet, X; Gabriel, R; Gisbert, JP; González, L; Pajares, JM; Roqué, M | 1 |
| Delves, HT; Phillips, RH; Powell, JJ; Seed, PT; Sieniawska, CE; Thompson, RP; Whitehead, MW | 1 |
| Champion, M; Lacey, S; Phillips, RH; Powell, JJ; Thompson, RP; Whitehead, MW | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Kato, M; Sugiyama, T; Takeda, H | 1 |
| Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
| Thomson, AB | 1 |
| Ching, CK; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, WM | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R | 1 |
| Cooper, R; Miskovitz, P; Nagler, J | 1 |
| Lam, SK; Wang, WH; Wong, BC | 1 |
| Chiba, N | 1 |
| Blanco, M; Gisbert, JP; Pajares, JM | 1 |
| Mégraud, F | 1 |
| Akhunov, ED; Farztdinov, KM; Katayev, VA; Kazykhanov, NS; Khusnutdinov, SM; Nijevitch, AA; Sataev, VU | 1 |
| Baena Díez, JM; García Lareo, M; López Mompó, C; Rams Rams, F; Rosario Hernández Ibáñez, M; Teruel Gila, J | 1 |
| Cabezudo, JG; Ducóns, J; Gomollon, F; Guirao, R; Montoro, M; Santolaria, S | 1 |
| Mégraud, F; Roberts, P; Williamson, R | 1 |
| Marshall, BJ; Mégraud, F | 1 |
| Chan, CK; Chu, KM; Fung, FM; Hu, WH; Lai, KC; Lam, SK; Lau, GK; Leung, SY; Wang, WH; Wong, BC; Wong, WM; Yuen, MF; Yuen, ST | 1 |
| Dashkova, S; Farztdinov, KM; Kazykhanov, NS; Nijevitch, AA; Sataev, VU | 1 |
| El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Osato, MS; Saeed, MA | 1 |
| De Boer, WA; Jansen, JB; Janssen, MJ; Van Oijen, AH; Verbeek, AL | 1 |
| Eshraghian, MR; Fazel, A; Malekzadeh, R; Massarrat, S; Sotudehmanesh, R; Ziad-Alizadeh, B | 1 |
| Kearney, DJ | 1 |
| Chejfec, G; O'Connell, S; Schnell, T; Seidel, J; Sonnenberg, A; Sontag, SJ | 1 |
| Bravo, JC; Bravo, LE; Casabon, AL; Collazos, T; Correa, P; Fischbach, LA; Ramirez, H; Realpe, JL; Ruiz, B; Schmidt, BA | 1 |
| Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V | 1 |
| Andriulli, A; Annese, V; Niro, GA; Perri, F; Quitadamo, M; Villani, MR | 1 |
| Hopkins, RJ | 1 |
| Dixon, CA; Hopkins, RJ; Meyer, JM; Siepman, NY; Silliman, NP; Sugg, JE | 1 |
| Delves, HT; Doig, LA; Phillips, RH; Powell, JJ; Sieniawska, CE; Thompson, RP; Whitehead, MW | 1 |
| Gisbert, JL; Gisbert, JP; Marcos, S; Pajares, JM | 2 |
| Campo, SM; De Matthaeis, M; Febbraro, I; Hassan, C; Lorenzetti, R; Morini, S; Porto, D; Zullo, A | 1 |
| Bardhan, KD; Mitchell, TR; Morris, P; Morton, D; Perry, MJ; Roberts, PM; Rowland, A; Sanders, DS; Thompson, M | 1 |
| Bayerdörffer, E; Graham, DY; Miehlke, S | 1 |
| Ananthakrishnan, N; Badrinath, S; Kate, V | 1 |
| Amini, M; Kamalian, N; Kaviani, MJ; Malekzadeh, R; Massarrat, S; Sotoudeh, M; Vahedi, H | 1 |
| Bujanda, L; Cosme, A; Iriondo, C; Muñoz, C; Sánchez, A; Santos, A | 1 |
| Beales, IL | 1 |
| Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
| Doulgeroglou, V; Kamberoglou, D; Patra, E; Polymeros, D; Sanidas, I; Savva, S; Tzias, V | 1 |
| Dudik, TV; Il'chenko, AA; Kaprel'yants, AS; Loginov, AS; Reshetnyak, VI; Vostroknutova, GN | 1 |
| Corder, FA; Howden, CW; Sahai, AV; Sharma, VK | 1 |
| Fang, XC; Hu, PJ; Li, ZS; Lu, H; Lu, XH; Xiao, SD; Zhang, DZ | 1 |
| De Francesco, V; Faleo, D; Hassan, C; Ierardi, E; Morini, S; Panella, C; Zullo, A | 1 |
| Annibale, B; Bordi, C; Caruana, P; D'Ambra, G; Delle Fave, G; Di Giulio, E; Grossi, C; Lahner, E; Milione, M | 1 |
| Artikis, V; Georgopoulos, SD; Karatapanis, S; Ladas, SD; Mentis, A; Raptis, SA; Spiliadi, C; Triantafyllou, K | 1 |
| Markova, T; Schwartz, K | 1 |
| Amsler, KM; Foster, LA; Merrill, JJ; Modzelewski, TC; Quispe, JD; Sizemore, CF; Slee, AM; Stevenson, DA | 1 |
| Andriulli, A; Clemente, R; Festa, V; Merla, A; Perri, F; Quitadamo, M | 1 |
| Takahashi, S; Tanaka, A | 1 |
| Ohkusa, T; Sato, N | 1 |
| Gómez Rodríguez, B; Hergueta Delgado, P; Herrerías Gutiérrez, JM; Mendoza Olivares, FJ; Pellicer Bautista, FJ; Rojas Feria, M; Romero Castro, R | 1 |
| Bird, N; Butcher, GP; Haqqani, MT; Hughes, SJ; Rhodes, JM; Ryder, SD; Stewart, M | 1 |
| Katelaris, P | 1 |
| Bell, GD; Powell, K | 1 |
| Bär, W; Freise, J; Gebel, M; Gladziwa, U; Haruma, K; Lange, P; Schmidt, FW; Wagner, S | 1 |
| Seppälä, K | 1 |
| Muñoz, DJ; Pybus, J; Tasman-Jones, C | 1 |
| Ainley, C; Chandrakumaran, K; D'Anna, L; Falzon, M; Holton, J; McNeil, I; Osborn, J; Romanos, A; Vaira, D | 1 |
| Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY | 1 |
| Bellis, D; Boero, M; Chiandussi, L; Di Napoli, A; Petrino, R | 1 |
| Adeyemi, EO; al-Homsi, M; Boehme, D; Fadlalla, H; Goodwin, S; Nnalue, NA; Sim, AJ | 1 |
| Corbishley, CM; Goggin, PM; Jackson, PA; Marrero, JM; Northfield, TC; Spychal, RT | 1 |
| Chiba, N; Hunt, RH; Rademaker, JW; Rao, BV | 1 |
| Garner, A | 1 |
| Demling, L | 1 |
| Bell, GD; Bolton, G; Brooks, S; Burridge, SM; Gant, PW; Harrison, G; Powell, KU; Prosser, S; Purser, K; Spencer, G | 1 |
| Duriex, DE; Madan, E; Midkiff, BR; Subik, MA; Westblom, TU | 1 |
| Littlewood, JM; Mahony, MJ; Wyatt, JI | 1 |
| Cave, DR | 1 |
| Beattie, S; Keane, C; O'Morain, C; Patchett, S | 1 |
| Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA | 1 |
| Andrews, P; Borody, TJ; Brandl, S; Devine, M; George, LL; Lenne, J; Moore-Jones, D; Walton, M | 1 |
| Blecker, U; Lanciers, S; Peeters, S; Vandenplas, Y | 1 |
| Glassman, MS | 1 |
| Alpert, LC; Evans, DG; Evans, DJ; Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM | 1 |
| Beattie, S; Keane, C; Leen, E; O'Morain, C; Patchett, S | 1 |
| Goh, KL; Lo, YL; Parasakthi, N; Peh, SC; Puthucheary, SD; Wong, NW | 1 |
| Casaubón-Garcín, P; Cervantes, R; Ramírez-Mayans, J; Tovar-Calderón, S | 1 |
| Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S | 1 |
| Balzano, A; Di Blasi, A; Gigliotti, T; Mosca, S; Piccirillo, MM; Rocco, VP | 1 |
| Chittajalu, R; Dahill, SW; el Nujumi, AM; Fullarton, GM; Hilditch, TE; MacDonald, AM; McColl, KE | 1 |
| Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM | 1 |
| Ali, MR; Brown, P; Hamilton, I; Lane, M; Morris, A; Nicholson, G; Samarasinghe, D | 1 |
| Alpert, LC; Evans, DG; Evans, DJ; Graham, DY; Jerdack, GR; Klein, PD; Morgan, DR; Opekun, A | 1 |
| Bell, GD; Jobson, RC; Weil, J; Williams, PF | 1 |
| Bokemeyer, B; Freise, J; Fritsch, RS; Iserhard, R; Schmidt, FW; Soudah, B; Wagner, S; Weissbrodt, H | 1 |
| Ali, MR; Blaser, MJ; Morris, AJ; Nicholson, GI; Perez-Perez, GI | 1 |
| Avunduk, C; Eastwood, GL; Gang, D; Polakowski, N; Suliman, M | 1 |
| Korsten, MA; Lateef, SK; Lieber, CS; Paronetto, F; Uppal, R | 1 |
| Campbell, AN | 1 |
| Raedsch, R | 1 |
| Gorodinskaia, VS; Il'chenko, AA; Zhukhovitskiĭ, BG; Zurabishvili, NG | 1 |
| Colimon, R; Flourié, B; Lavergne, A; Mignon, M; Modigliani, R; Rambaud, JC; Sobhani, I | 1 |
| Ahmed, W; Alam, SM; Jafarey, NA; Kazi, AM; Kazi, JI; Qureshi, H; Zuberi, SJ | 1 |
| Korman, MG | 1 |
| Loizeau, E | 1 |
| Börsch, GM; Graham, DY | 1 |
| Annibale, B; Corleto, V; de Magistris, L; Delle Fave, G; Giordano, E; Puoti, M; Torsoli, A | 1 |
| Islam, S; McLean, AJ | 1 |
208 review(s) available for bismuth and Infections, Helicobacter
| Article | Year |
|---|---|
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors | 2022 |
Treatment of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Penicillins; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2021 |
Nickel, an essential virulence determinant of Helicobacter pylori: Transport and trafficking pathways and their targeting by bismuth.
Topics: Animals; Bacterial Proteins; Bismuth; Helicobacter Infections; Helicobacter pylori; Mice; Nickel; Virulence; Virulence Factors | 2022 |
High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2022 |
Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2023 |
The management of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Stomach Neoplasms; Treatment Outcome | 2022 |
The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Third-line and rescue therapy for refractory
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline | 2023 |
Bismuth nanoparticles against microbial infections.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metal Nanoparticles | 2022 |
Comparison of multiple treatment regimens in children with
Topics: Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Treatment Outcome | 2023 |
Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Minocycline; Randomized Controlled Trials as Topic; Tetracycline; Treatment Outcome | 2023 |
Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of
Topics: Anti-Bacterial Agents; Bismuth; Diarrhea; Dietary Supplements; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Treatment Outcome | 2023 |
Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.
Topics: Anti-Bacterial Agents; Asian; Bismuth; Drug Therapy, Combination; Ethanol; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Failure | 2023 |
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium | 2019 |
High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Chile; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prevalence; Prospective Studies | 2019 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Vitamins | 2020 |
Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota.
Topics: Anti-Bacterial Agents; Asia; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin | 2020 |
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath Tests; Clarithromycin; Culture Techniques; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Feces; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Nitro Compounds; Organometallic Compounds; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Rifabutin; Salicylates; Salvage Therapy; Serologic Tests; Stomach Neoplasms; Tetracycline; Thiazoles; Treatment Outcome; Urea | 2020 |
Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Proton Pump Inhibitors | 2021 |
Treatment of Helicobacter pylori infection: a clinical practice update.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Meta-Analysis as Topic; Practice Guidelines as Topic; Probiotics; Proton Pump Inhibitors; Salvage Therapy; Systematic Reviews as Topic | 2021 |
Efficacy of second-line regimens for
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline | 2020 |
Review - Treatment of Helicobacter pylori infection 2020.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2020 |
Topics: Amoxicillin; Anti-Bacterial Agents; Biological Products; Bismuth; Clarithromycin; Drug Therapy, Combination; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Phytochemicals; Plant Extracts; Plants, Medicinal; Probiotics | 2020 |
Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline; Treatment Failure | 2021 |
Treatment of Refractory
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2022 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Topics: Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Iran; Treatment Outcome | 2017 |
[[Overview Basic Provisions Consensus of the III Working Italian Group for Diagnosis and Treatment of H.Pylory-Infection].]
Topics: Animals; Anti-Bacterial Agents; Bismuth; Breath Tests; Congresses as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Probiotics; Proton Pump Inhibitors; Stomach Neoplasms | 2016 |
[Drug susceptibility test guided therapy and novel empirical quadruple therapy for
Topics: Anti-Bacterial Agents; Asian People; Bismuth; Combined Modality Therapy; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Helicobacter pylori management in ASEAN: The Bangkok consensus report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Consensus; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Proton Pump Inhibitors; Taiwan; Tetracycline; Thailand; Treatment Outcome; United States | 2018 |
Treatment of Helicobacter pylori infection 2017.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Treatment of Helicobacter pylori infection: A clinical practice update.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Failure | 2018 |
Helicobacter Pylori Infection.
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Monoclonal; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Urea | 2018 |
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2018 |
Toward population specific and personalized treatment of Helicobacter pylori infection.
Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Models, Theoretical | 2018 |
Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2019 |
High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2019 |
Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2019 |
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Tetracycline; United States | 2019 |
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Treatment Failure | 2013 |
Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2013 |
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2013 |
Optimum duration of regimens for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Quinolones | 2013 |
Evidence-based recommendations for successful Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2014 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
[New guidelines for Helicobacter pylori treatment: comparisons between Korea and Japan].
Topics: Anti-Bacterial Agents; Antibodies; Bismuth; Disease Eradication; Drug Administration Schedule; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lymphoma, B-Cell, Marginal Zone; Republic of Korea; Stomach Neoplasms | 2014 |
Practical treatment of Helicobacter pylori: a balanced view in changing times.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Failure; Treatment Outcome | 2014 |
Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Polymerase Chain Reaction; Proton Pump Inhibitors; Treatment Outcome | 2014 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms | 2014 |
Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Practical Aspects in Choosing a Helicobacter pylori Therapy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Proton Pump Inhibitors; Treatment Outcome | 2015 |
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2015 |
Helicobacter pylori treatment: Still a work in progress.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Helicobacter pylori therapy: a paradigm shift.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Standard of Care; Treatment Outcome | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2016 |
Eradication of Helicobacter pylori Infection.
Topics: Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2016 |
IV Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Delphi Technique; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Meta-Analysis as Topic; Probiotics; Proton Pump Inhibitors; Recurrence; Salvage Therapy; Stomach Neoplasms; Stomach Ulcer; Treatment Failure | 2016 |
Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Network Meta-Analysis; Practice Guidelines as Topic; Proton Pump Inhibitors | 2016 |
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Randomized Controlled Trials as Topic | 2008 |
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine; Tinidazole; Treatment Outcome | 2009 |
Helicobacter pylori: diagnosis and treatment.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ofloxacin; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Treatment Failure | 2009 |
Pylera for the eradication of Helicobacter pylori infection.
Topics: Administration, Oral; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Randomized Controlled Trials as Topic; Tetracycline; Treatment Outcome | 2009 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Outcome Assessment, Health Care; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2010 |
Antimicrobial resistance and eradication strategies for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Mutation; Proton Pump Inhibitors | 2009 |
[Optimization of treatment of patients with diseases associated with Helicobacter pylori infection: justifying of bismuth preparations using].
Topics: Antacids; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2009 |
Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2010 |
[The association between Helicobacter pylori and gastric cancer: the role of infection's eradication. Recent advances].
Topics: Anti-Bacterial Agents; Bismuth; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors; Stomach Neoplasms | 2010 |
Iron deficiency anaemia can be improved after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Treatment of Helicobacter pylori infection 2010.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Treatment Outcome | 2010 |
Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis.
Topics: Aza Compounds; Bismuth; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Humans; Moxifloxacin; Quinolines; Treatment Outcome | 2011 |
Diagnosis and treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Stomach Neoplasms; Tetracycline | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Tetracycline | 2011 |
The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans | 2012 |
Review article: bismuth-based therapy for Helicobacter pylori eradication in children.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2012 |
[Helicobacter pylori - 2012].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Emigrants and Immigrants; Endoscopy, Gastrointestinal; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Hungary; In Situ Hybridization, Fluorescence; Levofloxacin; Ofloxacin; Peptic Ulcer; Polymerase Chain Reaction; Stomach Neoplasms | 2012 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Proton Pump Inhibitors; Ranitidine; Salicylates; Virulence | 2002 |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Ditiocarb; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2003 |
Is it time for quadruple therapy to be first line?
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine | 2003 |
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2004 |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Topics: Antacids; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Guideline Adherence; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline; Treatment Outcome | 2004 |
Treatment of H. pylori infection: a review.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Clarithromycin; Fluoroquinolones; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Ofloxacin; Polypharmacy; Ranitidine; Rifabutin | 2005 |
Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2005 |
Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine | 2005 |
Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure | 2005 |
[Anti-Helicobacter pylori quadruple therapy].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2005 |
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Treatment Failure | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2006 |
First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004.
Topics: Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pumps; Ranitidine; Time Factors; Treatment Outcome | 2006 |
Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.
Topics: Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Ranitidine | 2007 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 2008 |
Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?
Topics: Abdominal Pain; Antidepressive Agents; Bismuth; Calcium Channel Blockers; Cholecystokinin; Dyspepsia; Gastric Emptying; Helicobacter Infections; Humans; Narcotics; Nitric Oxide; Prostaglandins, Synthetic | 1995 |
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Recurrence | 1995 |
[Helicobacter pylori infection and non-ulcer dyspepsia].
Topics: Bismuth; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 1995 |
Helicobacter pylori eradication up to date.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans | 1995 |
Eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Recurrence; Stomach Neoplasms; Stomach Ulcer | 1994 |
Treating peptic ulcer: an ongoing challenge.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline | 1995 |
[Status of ranitidine in eradication of Helicobacter pylori].
Topics: Amoxicillin; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Ranitidine | 1995 |
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Peptic Ulcer; Treatment Outcome; Uncoupling Agents | 1995 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tinidazole | 1994 |
[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Long-Term Care; Male; Middle Aged; Omeprazole; Peptic Ulcer; Recurrence; Sucralfate | 1993 |
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Immunologic Techniques; Lymphoma, Non-Hodgkin; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1994 |
[How to eradicate Helicobacter pylori?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Omeprazole | 1994 |
Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1994 |
[Helicobacter pylori infection in children].
Topics: Adolescent; Adult; Amoxicillin; Bismuth; Child; Child, Preschool; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Prognosis | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; United States | 1994 |
[Current therapy of Helicobacter pylori-induced chronic gastritis and/or peptic ulcer].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1994 |
Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics.
Topics: Aged; Amoxicillin; Biopsy; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Ranitidine; Salicylates; Stomach; Stomach Neoplasms | 1994 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1994 |
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Metronidazole; Peptic Ulcer; Recurrence; Treatment Outcome | 1994 |
[Treatment of Helicobacter pylori infection in children].
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Recurrence; Treatment Outcome | 1994 |
Duodenal ulcer treatment: progress from pH to HP.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Tetracycline | 1994 |
A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia.
Topics: Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Patient Compliance; Random Allocation | 1994 |
[Alternatives of drug therapy in Helicobacter pylori infections].
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Oxytetracycline | 1994 |
[Effective regimen for eradication of Helicobacter pylori].
Topics: Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1993 |
[Helicobacter pylori infections].
Topics: Amphotericin B; Bismuth; Clarithromycin; Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Tetracyclines | 1993 |
Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Topics: Amoxicillin; Bismuth; Cimetidine; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Patient Compliance; Peptic Ulcer; Tinidazole | 1993 |
Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1993 |
Helicobacter pylori infection.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Stomach Neoplasms; Stomach Ulcer; Tetracycline | 1993 |
Treatment strategies for Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1993 |
[Treatment of Helicobacter pylori infection: current status].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Time Factors | 1995 |
Eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 1995 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Contraindications; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Misoprostol; Peptic Ulcer; Predictive Value of Tests; Proton Pump Inhibitors; Recurrence | 1996 |
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Omeprazole; Penicillins; Regression Analysis; Stomach Ulcer; Tetracycline; Time Factors | 1996 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; Cholelithiasis; Chronic Disease; Cisapride; Diagnosis, Differential; Domperidone; Dopamine Antagonists; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metoclopramide; Peptic Ulcer; Piperidines; Stomach Neoplasms | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Stomach Neoplasms; Stomach Ulcer; Tetracycline; Time Factors | 1996 |
Helicobacter pylori and complicated ulcer disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer Hemorrhage; Risk Factors; Stomach Ulcer | 1996 |
[Treatment of Helicobacter pylori infection].
Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Middle Aged; Omeprazole; Stomach Ulcer | 1996 |
Current indications for Helicobacter pylori eradication therapy.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Stomach Neoplasms; Stomach Ulcer | 1996 |
Review of Helicobacter pylori eradication regimens.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole | 1996 |
Eradication of Helicobacter pylori: omeprazole in combination with antibiotics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Time Factors; Treatment Failure | 1996 |
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Omeprazole; Penicillins; Ranitidine | 1996 |
How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1996 |
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitals, University; Humans; Metronidazole; Norway; Oxytetracycline; Peptic Ulcer; Stomach Diseases; Urea; Urease | 1996 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracyclines; Tinidazole | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline; Tinidazole; Treatment Outcome | 1996 |
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Nitroimidazoles; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Risk Assessment; Tetracyclines | 1996 |
Helicobacter pylori infection. The importance of eradication in patients with gastric disease.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1996 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1996 |
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monte Carlo Method; Organometallic Compounds; Patient Compliance; Proton Pump Inhibitors; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1997 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1997 |
Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
Treatment of Helicobacter pylori infection: a review.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Patient Compliance; Vaccines | 1997 |
Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors | 1997 |
The actions of bismuth in the treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Synergism; Duodenum; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Organometallic Compounds; Ranitidine; Salicylates; Treatment Outcome | 1997 |
The treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma; Proton Pump Inhibitors; Ranitidine; Risk Factors; Stomach Neoplasms | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Protein Synthesis Inhibitors; Salicylates; Tetracycline | 1997 |
Review: Helicobacter pylori. Current issues and new directions.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1997 |
Peptic ulcer disease in the 1990s: an Asian perspective.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asia; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer | 1997 |
New developments in Helicobacter pylori eradication therapy.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1997 |
Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Tinidazole | 1997 |
Treatment of Helicobacter pylori infection: a review of the world literature.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Smoking; Tetracycline; Treatment Outcome | 1996 |
Therapy of H. pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine; Tinidazole | 1997 |
Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1997 |
Helicobacter pylori.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Bismuth; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma; Peptic Ulcer; Stomach Neoplasms | 1998 |
[Helicobacter infections].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Risk Factors; Stomach Neoplasms; Stomach Ulcer | 1997 |
New options in Helicobacter pylori eradication: efficacy, resistance and synergy.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1998 |
[Treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Tetracycline; Time Factors | 1998 |
Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer.
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Interactions; Duodenal Ulcer; Formularies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 1998 |
Management of Helicobacter pylori infection in children.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Patient Selection | 1998 |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 1998 |
Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Azithromycin; Bismuth; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Meta-Analysis as Topic; Peptic Ulcer | 1998 |
[History of the treatment of Helicobacter pylori and clinical efficacy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Practice Guidelines as Topic; Proton Pump Inhibitors | 1999 |
[Characteristics of anti-microbial agents and its clinical choice for H. pylori treatment].
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Nitroimidazoles | 1999 |
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Neoplasms; Endoscopy, Digestive System; Enzyme Inhibitors; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Organometallic Compounds; Peptic Ulcer; Practice Guidelines as Topic; Proton Pump Inhibitors; Ranitidine; Stomach Neoplasms | 1998 |
Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Multivariate Analysis; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors | 1999 |
Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Pilot Projects; Ranitidine; Treatment Outcome | 1999 |
Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Global Health; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Regression Analysis | 1999 |
[A consensus on some problems of Helicobacter pylori (draft)].
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Stomach Ulcer | 1997 |
Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline; Treatment Outcome | 1999 |
[Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Duodenitis; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lymphoma, B-Cell, Marginal Zone; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Ranitidine; Stomach Neoplasms; Stomach Ulcer | 1999 |
Where are We with current therapy?
Topics: Adult; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 2000 |
Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2000 |
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine | 2000 |
Traditional and non-traditional antimicrobial agents for H. pylori infection.
Topics: Bismuth; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2000 |
Therapy for H. pylori infection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine; Stomach Diseases | 1999 |
How to treat Helicobacter pylori. First-line, second-line, and future therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Protocols; Costs and Cost Analysis; Drug Therapy, Combination; Forecasting; Genetics, Medical; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2000 |
Retreatment of Helicobacter pylori infection after initial treatment failure.
Topics: Anti-Ulcer Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine; Retreatment; Treatment Failure | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Odds Ratio; Omeprazole; Ranitidine; Research Design; Retrospective Studies; United States; United States Food and Drug Administration | 2001 |
Treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; MEDLINE; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer Hemorrhage; Randomized Controlled Trials as Topic; Ranitidine; Recurrence; Risk Factors; Salicylates; Sensitivity and Specificity | 2001 |
A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracyclines | 2001 |
[Classic triple therapy for Helicobacter pylori infection].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Histamine H2 Antagonists; Humans; Metronidazole; Patient Care Planning; Penicillins; Proton Pumps; Ranitidine; Recurrence | 2002 |
[Should Helicobacter infection be treated?].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1991 |
Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefixime; Cefotaxime; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Research Design; Sensitivity and Specificity | 1992 |
[Future perspectives of ulcer therapy].
Topics: Anti-Ulcer Agents; Bismuth; Forecasting; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1992 |
Therapeutic approaches to recurrent peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Recurrence; Salicylates | 1992 |
Helicobacter pylori infection in children. A clinical overview.
Topics: Anti-Bacterial Agents; Biopsy; Bismuth; Child; Clinical Trials as Topic; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Evaluation Studies as Topic; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence; Salicylates | 1992 |
[Helicobacter pylori: can it be a contributing factor in peptic ulcer in childhood?].
Topics: Anti-Bacterial Agents; Bismuth; Child; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1991 |
The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; History, 18th Century; History, 19th Century; History, 20th Century; Humans | 1991 |
[Bismuth therapy in gastroenterology].
Topics: Bismuth; Diarrhea; Gastritis; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1991 |
[Helicobacter pylori and gastroduodenal pathology. Second part: Clinical aspects and therapy].
Topics: Achlorhydria; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Stomach Ulcer | 1991 |
Helicobacter pylori: fact or fiction?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence | 1990 |
The who's and when's of therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1990 |
350 trial(s) available for bismuth and Infections, Helicobacter
| Article | Year |
|---|---|
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome | 2021 |
Comparison of tailored
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Republic of Korea; Treatment Outcome | 2022 |
The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Potassium Citrate; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Tetracycline; Treatment Outcome | 2021 |
Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2022 |
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Rabeprazole; Treatment Outcome | 2022 |
A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Prospective Studies | 2022 |
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2022 |
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Saccharomyces boulardii; Treatment Outcome | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 16S; Tetracycline; Treatment Outcome | 2022 |
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Treatment Outcome | 2022 |
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2022 |
[The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus].
Topics: Anti-Bacterial Agents; Bismuth; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies; Treatment Outcome | 2022 |
[A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of
Topics: Amoxicillin; Anti-Bacterial Agents; Bifidobacterium longum; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterococcus faecium; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A, Secretory; Omeprazole; Probiotics; Prospective Studies; Urease | 2021 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2023 |
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Probiotics modulate gastrointestinal microbiota after
Topics: Anti-Bacterial Agents; Bacteroidetes; Bismuth; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; RNA, Ribosomal, 16S | 2022 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Pharmacokinetic Interaction of Anaprazole, Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese Subjects.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Combinations; East Asian People; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult | 2023 |
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome | 2023 |
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefuroxime; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Medication Adherence; Metronidazole; Minocycline; Penicillins; Tetracycline; Treatment Outcome | 2023 |
A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2023 |
Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Taiwan; Treatment Outcome | 2023 |
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Potassium Citrate; Tetracycline | 2023 |
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2023 |
Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2023 |
Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Comparison of the efficacies of triple, quadruple and sequential antibiotic therapy in eradicating Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 2023 |
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2023 |
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Topics: Adult; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2023 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Rabeprazole; Randomized Controlled Trials as Topic; Single-Blind Method | 2023 |
Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bismuth; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Thailand | 2023 |
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome | 2019 |
High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Topics: Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Probiotics; Prognosis; Proton Pump Inhibitors; Thailand | 2019 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
[The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Russia; Stomach Ulcer | 2019 |
Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 2020 |
Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Disulfides; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Sulfinic Acids; Treatment Outcome | 2021 |
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Treatment Outcome | 2020 |
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2020 |
The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ofloxacin; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Republic of Korea | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2021 |
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Endoscopy; Esomeprazole; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Transmission; Organometallic Compounds; Proton Pump Inhibitors; Salts | 2021 |
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
Topics: Abdominal Pain; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Probiotics; Treatment Outcome | 2022 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Treatment Outcome | 2021 |
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Syria; Tinidazole; Treatment Outcome; Young Adult | 2021 |
[A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2021 |
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Medication Adherence; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Failure; Urea | 2017 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors | 2017 |
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Taiwan; Tetracycline; Treatment Outcome | 2017 |
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors | 2017 |
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2018 |
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Young Adult | 2017 |
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea | 2018 |
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates | 2018 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline; Young Adult | 2018 |
Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteriological Techniques; Bismuth; Breath Tests; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; United States; Young Adult | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2018 |
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Topics: Adult; Amoxicillin; Bismuth; Breath Tests; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline | 2018 |
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Young Adult | 2018 |
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Probiotics; Proton Pump Inhibitors; Retrospective Studies; Tetracycline | 2018 |
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2018 |
Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2019 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome | 2018 |
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2019 |
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Patient Education as Topic; Pectins; Prospective Studies; Text Messaging; Young Adult | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2019 |
[Influence of different timing of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Disease Eradication; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Saccharomyces boulardii; Treatment Outcome | 2019 |
Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duration of Therapy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Treatment Outcome | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult | 2013 |
The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Female; Helicobacter Infections; Humans; Male; Middle Aged; Peptic Ulcer; Placebos; Probiotics; Treatment Outcome; Urea | 2013 |
Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pilot Projects; Prospective Studies; Treatment Outcome; Urea; Young Adult | 2013 |
The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Young Adult | 2013 |
Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Tetracycline; Time Factors; Treatment Outcome | 2014 |
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Young Adult | 2013 |
[Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Probiotics; Prognosis; Prospective Studies; Salicylates; Thailand | 2014 |
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Urea | 2015 |
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2015 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Topics: Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Thailand | 2015 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Cytochrome P-450 CYP2C19; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tertiary Care Centers; Treatment Outcome; Young Adult | 2016 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinical Protocols; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Salicylates; Turkey | 2015 |
Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety.
Topics: Adult; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Phytotherapy; Plant Extracts; Treatment Outcome; Young Adult | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult | 2015 |
[Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
Topics: Amoxicillin; Antacids; Bismuth; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Gastritis; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Urea | 2016 |
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tetracycline; Treatment Failure | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2017 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2009 |
The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Tetracyclines; Treatment Outcome | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2009 |
The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Ascorbic Acid; Bismuth; Dietary Supplements; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Young Adult | 2009 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Ranitidine | 2009 |
A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; China; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Pilot Projects; Placebos; Rural Population; Tetracycline; Urea | 2010 |
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tetracycline; Time Factors; Treatment Outcome | 2010 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Case-Control Studies; Chi-Square Distribution; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Surveys and Questionnaires; Tetracycline; Treatment Outcome | 2010 |
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Bismuth; Clarithromycin; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Omeprazole; Pectins; Prospective Studies | 2010 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Peptic Ulcer; Treatment Outcome | 2011 |
[Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dental Plaque; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Failure; Young Adult | 2011 |
[Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Humans; Male; Middle Aged; Treatment Outcome | 2011 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Medication Adherence; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histocytochemistry; Humans; Italy; Male; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea; Young Adult | 2011 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Middle Aged; Organometallic Compounds; Pantoprazole | 2012 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline; Young Adult | 2012 |
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Bismuth; Carotenoids; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lycopene; Male; Metronidazole; Middle Aged; Omeprazole; Treatment Outcome | 2012 |
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome; Urea; Young Adult | 2013 |
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Proton Pumps; Treatment Failure; Treatment Outcome | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pantoprazole; Peptic Ulcer; Prospective Studies; Sulfoxides; Tetracycline; Treatment Failure; Treatment Outcome | 2002 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome | 2002 |
One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Treatment Outcome | 2002 |
Effectiveness of ranitidine bismuth citrate based triple therapy for treating Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Prospective Studies; Ranitidine; Stomach; Thailand; Treatment Outcome | 2002 |
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Tetracycline | 2002 |
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenitis; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Ranitidine; Spiramycin; Time Factors | 2002 |
Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 2003 |
Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.
Topics: Adult; Amoxicillin; Antacids; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Dyspepsia; Female; Gastric Acidity Determination; Gastritis, Atrophic; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Risk Factors; Salicylates; Tetracycline | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salvage Therapy; Tetracyclines; Urea | 2003 |
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Tetracycline; Urea | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Tetracycline | 2003 |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Compliance; Prospective Studies; Treatment Outcome | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Ranitidine; Time Factors; Urea | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Tinidazole; Treatment Outcome | 2003 |
Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Proteins; Bismuth; Blood Pressure; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Male; Middle Aged; Prevalence; Ranitidine | 2003 |
Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Oxytetracycline; Specimen Handling; Treatment Outcome | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Drug Resistance, Bacterial; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Ranitidine; Tetracycline; Treatment Outcome | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 2004 |
[Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Aza Compounds; Bismuth; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Quinolines | 2005 |
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tetracycline; Treatment Outcome; Turkey | 2005 |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2005 |
One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome | 2005 |
Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Citric Acid; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Predictive Value of Tests; Salicylates; Sensitivity and Specificity; Treatment Outcome; Urea | 2005 |
Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Anti-Bacterial Agents; Biological Availability; Bismuth; Cross-Over Studies; Drug Combinations; Food-Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Screening; Middle Aged; Patient Acceptance of Health Care; Peptic Ulcer; Quality of Life; Ranitidine | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Prospective Studies; Ranitidine | 2006 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Ranitidine; Tetracycline; Treatment Outcome; Urease; Young Adult | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Contraindications; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Pyloric Antrum; Stomach Ulcer; Tetracycline; Treatment Failure | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; Double-Blind Method; Dyspepsia; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Metronidazole; Omeprazole; Peptic Ulcer; Sucrose; Tetracycline; Treatment Outcome | 2006 |
Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ranitidine; Treatment Failure; Treatment Outcome | 2007 |
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 2007 |
First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Ranitidine; Treatment Outcome | 2007 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome | 2007 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Cross-Over Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Urea | 2008 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1995 |
Healing of gastric body ulcer with gastroprotective versus antisecretory treatment.
Topics: Adult; Antacids; Anti-Ulcer Agents; Bismuth; Cimetidine; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Ranitidine; Recurrence; Stomach Ulcer; Time Factors | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Recurrence | 1995 |
[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression].
Topics: Aluminum Hydroxide; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Magnesium Hydroxide; Metronidazole; Omeprazole; Simethicone; Stomach Ulcer; Tetracycline | 1995 |
Bismuth salts and neurotoxicity. A randomised, single-blind and controlled study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Electroencephalography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Nervous System; Neurologic Examination; Organometallic Compounds; Single-Blind Method | 1995 |
Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up.
Topics: Adult; Aged; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Spiramycin; Treatment Outcome | 1995 |
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Topics: Adult; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Time Factors | 1995 |
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Recurrence; Tetracycline; Time Factors | 1995 |
Effect of administration of ranitidine bismuth citrate with food on the suppression and eradication of Helicobacter pylori in infected volunteers.
Topics: Adult; Bismuth; Breath Tests; Carbon Radioisotopes; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Food; Headache; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Incidence; Male; Ranitidine; Time Factors; Urea | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Nitrates; Omeprazole; Prospective Studies; Ranitidine; Recurrence; Tetracycline; Time Factors; Tinidazole | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Sucralfate; Tetracycline | 1995 |
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.
Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 1995 |
Association of symptoms with Helicobacter pylori infection in children.
Topics: Adolescent; Biopsy; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Duodenum; Female; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Prospective Studies | 1995 |
A 1-h topical therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Male; Metronidazole; Middle Aged; Pronase; Time Factors; Treatment Outcome | 1995 |
Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Antacids; Bismuth; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Prospective Studies; Quality of Life; Recurrence; Severity of Illness Index; Time Factors | 1994 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Stomach | 1994 |
Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth.
Topics: Azithromycin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Recurrence | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Leukocytes; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pumps; Recurrence | 1994 |
Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Tetracycline; Time Factors | 1994 |
Roxithromycin in the eradication of Helicobacter pylori.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Organometallic Compounds; Piperidines; Roxithromycin | 1994 |
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 1994 |
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Stomach Ulcer; Tetracycline | 1994 |
Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Time Factors | 1994 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Recurrence | 1994 |
[The effect of the eradication of H. pylori on the intractable ulcer].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline | 1993 |
Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial.
Topics: Adult; Bismuth; Chronic Disease; Double-Blind Method; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Leukocyte Count; Organometallic Compounds; Salicylates; Treatment Outcome | 1993 |
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline | 1993 |
Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Cisapride; Double-Blind Method; Duodenum; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Piperidines; Pyloric Antrum | 1993 |
Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Stomach Ulcer; Tetracycline | 1993 |
Patient factors affecting Helicobacter pylori eradication with triple therapy.
Topics: Adult; Age Factors; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Marriage; Metronidazole; Middle Aged; Multivariate Analysis; Patient Compliance; Prospective Studies; Recurrence; Stomach Ulcer; Tetracycline | 1993 |
GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer.
Topics: Adult; Bismuth; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Logistic Models; Male; Middle Aged; Ranitidine; Treatment Outcome | 1995 |
Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Penicillins; Recurrence; Salicylates | 1995 |
Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Palliative Care; Peptic Ulcer; Ranitidine; Treatment Outcome | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Salicylates; Single-Blind Method; Time Factors | 1996 |
Efficacy of ciprofloxacin in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies | 1996 |
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Recurrence; Salicylates; Stomach Ulcer; Time Factors; Tinidazole | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Tetracycline | 1995 |
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine; Recurrence | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Premedication; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors | 1996 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Recurrence; Serologic Tests; Tetracycline | 1996 |
One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Salicylates | 1996 |
Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without Helicobacter pylori infection.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Bismuth; Dose-Response Relationship, Drug; Double-Blind Method; Food; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Peptones; Placebos; Ranitidine; Stimulation, Chemical | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Malaysia; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Time Factors | 1996 |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer Hemorrhage; Stomach Ulcer; Tetracycline | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Penicillins; Prospective Studies; Recurrence; Time Factors | 1997 |
One week treatment for Helicobacter pylori infection.
Topics: Adolescent; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Organometallic Compounds | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Nizatidine; Omeprazole; Organometallic Compounds; Penicillins; Ranitidine; Salicylates | 1997 |
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Tetracycline; Time Factors | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Treatment Outcome | 1997 |
Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Life Tables; Male; Middle Aged; Ranitidine; Treatment Outcome; Wound Healing | 1997 |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Pyloric Antrum; Ranitidine | 1997 |
Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tetracycline | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders | 1997 |
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Naproxen; Organometallic Compounds; Prospective Studies; Stomach Ulcer; Tetracycline | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Smoking; Tetracycline; Tetracyclines | 1997 |
[Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin].
Topics: Abdominal Pain; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Longitudinal Studies; Male; Prospective Studies; Ranitidine; Recurrence | 1996 |
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Salicylates; Tetracycline; Urea | 1997 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peru; Recurrence; Salicylates; Tetracycline; Tinidazole | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin | 1997 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin; Stomach Ulcer | 1997 |
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Sucralfate; Tetracycline | 1997 |
One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer Hemorrhage; Ranitidine; Recurrence; Tetracycline | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anus Diseases; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hallucinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Omeprazole; Peptic Ulcer; Pregnancy; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Taste Disorders; Time Factors; Tongue Diseases; Treatment Outcome; Urea; Vomiting | 1998 |
Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid.
Topics: Adult; Aged; Analysis of Variance; Antacids; Bismuth; Chelating Agents; Gastritis; Helicobacter Infections; Humans; Middle Aged; Organometallic Compounds; Single-Blind Method; Succimer; Unithiol | 1998 |
Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine; Recurrence | 1997 |
Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study.
Topics: Adult; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer Hemorrhage; Prospective Studies; Recurrence | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Treatment Outcome | 1998 |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Ranitidine; Wound Healing | 1997 |
Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Stomach Ulcer; Tetracycline; Treatment Outcome | 1998 |
Helicobacter pylori eradication: kill the bug and save the pill?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Peptic Ulcer; Prospective Studies; Risk Factors; Single-Blind Method; Tetracycline | 1998 |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole | 1998 |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 1998 |
Addition of bismuth subnitrate to omeprazole plus amoxycillin improves eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Ranitidine; Stomach Ulcer | 1998 |
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Time Factors; Treatment Failure | 1998 |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pumps; Ranitidine; Single-Blind Method; Treatment Outcome | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome | 1998 |
Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Recurrence; Treatment Outcome | 1998 |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1998 |
Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Azithromycin; Bismuth; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome; Urea | 1999 |
Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man.
Topics: Adult; Bismuth; Ethanol; Female; Gastric Acid; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Organometallic Compounds; Salicylates | 1999 |
One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Tetracycline | 1999 |
[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clinical Protocols; Duodenal Ulcer; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Retrospective Studies; Treatment Outcome | 1998 |
Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Proton Pump Inhibitors; Ranitidine | 1999 |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Penicillins; Ranitidine; Stomach Ulcer | 1999 |
Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Patient Compliance; Ranitidine; Tetracycline; Urea | 1999 |
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori.
Topics: Adult; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Ranitidine; Time Factors | 1999 |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1999 |
Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Penicillins; Ranitidine; Urea | 1999 |
Garlic or jalapeño peppers for treatment of Helicobacter pylori infection.
Topics: Adult; Bismuth; Capsicum; Cross-Over Studies; Female; Garlic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Phytotherapy; Plants, Medicinal; Prospective Studies; Salicylates | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 1999 |
Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ranitidine | 1999 |
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Double-Blind Method; Drug Therapy, Combination; Female; Ferrous Compounds; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Intestinal Absorption; Male; Metronidazole; Nutritional Status; Organometallic Compounds; Placebos; Pyloric Antrum | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Colloids; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pectins | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 1999 |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Ranitidine | 1999 |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Penicillins; Peptic Ulcer; Prospective Studies; Ranitidine; Treatment Outcome | 1999 |
Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine; Turkey | 1999 |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 1999 |
A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Maintenance Organizations; Helicobacter Infections; Helicobacter pylori; Humans; Male; Massachusetts; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Program Evaluation; Salicylates; Tetracycline; Treatment Outcome | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Recurrence; Wound Healing | 1999 |
Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tinidazole; Treatment Outcome; Urea | 1999 |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Penicillins; Prospective Studies; Ranitidine; Tinidazole; Urea | 2000 |
Efficacy of a multistep strategy for Helicobacter pylori eradication.
Topics: Algorithms; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole; Treatment Failure | 2000 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline | 2000 |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Salvage Therapy | 2000 |
Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A; Male; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Urease; Vietnam | 2000 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Outlet Obstruction; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Prospective Studies; Ranitidine; Single-Blind Method | 2000 |
Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Treatment Failure | 2000 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Clarithromycin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pantoprazole; Ranitidine; Sulfoxides; Tinidazole | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Ferrets; Gastric Mucosa; Helicobacter; Helicobacter Infections; Ovariectomy; Ranitidine; Time Factors | 1999 |
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Patient Compliance; Prospective Studies; Salicylates; Tetracycline; Treatment Outcome | 2000 |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2000 |
[Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Time Factors | 2000 |
Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Middle Aged; Organometallic Compounds; Treatment Outcome | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Prognosis; Secondary Prevention | 2000 |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2000 |
[Effect of Helicobacter pylori eradication on histological lesions of gastric mucosa. An 18-month follow-up study].
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Severity of Illness Index; Treatment Outcome | 2000 |
Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Ranitidine; Tinidazole | 2000 |
Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Synergism; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine | 2000 |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Hong Kong; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Ranitidine; Treatment Outcome; Urea | 2001 |
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome; Urea | 2001 |
A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Treatment Outcome | 2001 |
Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Penicillins; Ranitidine; Veterans | 2001 |
Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Epithelium; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Male; Metronidazole; Middle Aged; Organometallic Compounds; Penicillins; Placebos; Risk Factors; Salicylates; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Headache; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pruritus; Ranitidine; Recurrence; Taste Disorders; Tinidazole; Treatment Outcome | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Ranitidine; Recurrence; Sulfoxides; Tinidazole; Treatment Outcome; Urea | 2001 |
Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Safety | 2001 |
High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 2001 |
A triple therapy regimen after failed Helicobacter pylori treatments.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Tetracycline; Tinidazole; Urea; Urease | 2001 |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome; Urea; Urease | 2001 |
Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Perforation; Prospective Studies; Ranitidine; Recurrence; Retrospective Studies; Tetracycline | 2001 |
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Bismuth; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esophagoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Urea | 2001 |
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2001 |
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Peptic Ulcer; Ranitidine; Retrospective Studies | 2001 |
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Diarrhea; Dizziness; Double-Blind Method; Drug Therapy, Combination; Exanthema; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Prospective Studies; Pruritus; Ranitidine; Tetracycline; Treatment Outcome; Vomiting | 2001 |
Two new treatment regimens for Helicobacter pylori eradication: a randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tinidazole; Treatment Outcome | 2001 |
Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment.
Topics: Acute Disease; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Male; Middle Aged; Serologic Tests; Time Factors | 2002 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Omeprazole; Tetracycline; Treatment Failure | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2002 |
Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection.
Topics: Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine | 2002 |
Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
Topics: Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine; Salicylates; Time Factors | 1992 |
Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Prospective Studies | 1992 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Single-Blind Method; Tetracycline | 1992 |
Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Bismuth; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metronidazole; Middle Aged; Ranitidine; Recurrence; Regression Analysis; Water | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection.
Topics: Bismuth; Clindamycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Pain Measurement; Salicylates | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Recurrence; Risk Factors; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Topics: Adult; Aged; Antacids; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Tetracycline | 1992 |
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies | 1991 |
Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate.
Topics: Adult; Antacids; Bismuth; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Recurrence | 1991 |
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates | 1991 |
Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Salicylates; Single-Blind Method; Tetracycline | 1991 |
Duodenal ulcer relapse after eradication of Helicobacter pylori.
Topics: Amoxicillin; Antacids; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Recurrence; Tinidazole | 1991 |
Chronic alcoholic gastritis. Roles of alcohol and Helicobacter pylori.
Topics: Adult; Alcoholism; Aluminum Hydroxide; Amoxicillin; Bismuth; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Temperance | 1991 |
A placebo controlled trial of bismuth salicylate in Helicobacter pylori associated gastritis.
Topics: Adolescent; Adult; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Placebos; Prospective Studies; Salicylates; Salicylic Acid | 1990 |
Medical treatment of antral gastrin cell hyperfunction: role of nonantisecretory therapy.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Bismuth; Cimetidine; Duodenal Ulcer; Enterochromaffin Cells; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine | 1990 |
362 other study(ies) available for bismuth and Infections, Helicobacter
| Article | Year |
|---|---|
Clinical audit of current
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Audit; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Singapore; Treatment Outcome | 2022 |
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastroenterologists; Gastroenterology; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Surveys and Questionnaires | 2022 |
Helicobacter pylori infection and eradication outcomes among Vietnamese patients in the same households: Findings from a non-randomized study.
Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Asian People; Bismuth; Child; Drug Therapy, Combination; Family Characteristics; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Tetracycline; Vietnam; Young Adult | 2021 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
All-in-One Theranostic Platform Based on Hollow Microcapsules for Intragastric-Targeting Antiulcer Drug Delivery, CT Imaging, and Synergistically Healing Gastric Ulcer.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Precision Medicine; Stomach Ulcer; Tetracycline; Tomography, X-Ray Computed | 2022 |
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Stomach Neoplasms; Systematic Reviews as Topic; Treatment Failure | 2022 |
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2022 |
Structure of the active pharmaceutical ingredient bismuth subsalicylate.
Topics: Bismuth; Helicobacter Infections; Humans; Organometallic Compounds; Pharmaceutical Preparations; Salicylates | 2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Poland; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Helicobacter pylori eradication in elderly patients: can we assume that a bismuth-based therapy is effective as in young people?
Topics: Adolescent; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2022 |
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome | 2022 |
Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cross-Sectional Studies; Drug Therapy, Combination; Gastroenterologists; Helicobacter Infections; Helicobacter pylori; Humans; Penicillins; Proton Pump Inhibitors; Tertiary Care Centers; Urea | 2022 |
Bacterial Membrane Vesicles as a Novel Strategy for Extrusion of Antimicrobial Bismuth Drug in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Polyphosphates; Stomach Neoplasms | 2022 |
Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Multiplex Polymerase Chain Reaction; Oligonucleotides; Retrospective Studies | 2023 |
Single-capsule bismuth-based quadruple therapy as a rescue therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Probiotics; RNA, Ribosomal, 16S; Treatment Outcome | 2022 |
Effects of Quadruple Therapy Combined with Probiotics on
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Motilin; Pectins; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Somatostatin; Tablets, Enteric-Coated | 2022 |
Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Prospective Studies; Proton Pump Inhibitors; Registries | 2023 |
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2022 |
Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rifabutin; Treatment Outcome; United States | 2023 |
Clinical Effects of Biling Weitong Granules in Combination with Quadruple Therapy on Refractory Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Treatment Outcome | 2023 |
Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Treatment Outcome | 2023 |
Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication?
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duration of Therapy; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Generalization and safety of the second-line levofl oxacin or Bismuth-based quadruple therapy for Helicobacter eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Failure; Treatment Outcome | 2023 |
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries | 2023 |
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
Topics: Amoxicillin; Anti-Bacterial Agents; Asia, Southeastern; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Physicians; Proton Pump Inhibitors; Surveys and Questionnaires | 2023 |
Comparison of the management of Helicobacter pylori infection between the older and younger European populations.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Penicillins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Helicobacter pylori Empirical and Tailored Eradication Therapy and Factors Influencing Eradication Rate: a 4-Year Single-Center Study.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Retrospective Studies; Treatment Outcome | 2023 |
Clinical Efficacy of Diet Intervention Combined with Bismuth Potassium Citrate in Helicobacter pylori-Related Chronic Atrophic Gastritis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Potassium; Potassium Citrate; Treatment Outcome | 2023 |
Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cross-Sectional Studies; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duration of Therapy; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Reply.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2019 |
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; Cross-Sectional Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2020 |
The effect of intracellular “depot” helicobacter pylori infection on the quality of eradication with monotheraphy of patients with chronic non-atrophic gastritis by the bismuth colloidal subcitrate
Topics: Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Disease Eradication; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Republic of Korea; Tertiary Care Centers; Tetracycline; Tetracycline Resistance | 2020 |
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Registries; Tetracycline | 2020 |
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2020 |
Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tetracycline | 2020 |
[European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Moscow; Prospective Studies; Proton Pump Inhibitors; Registries; Russia | 2020 |
Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2020 |
Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Drug Costs; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hypersensitivity; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Spain; Tetracycline; Treatment Outcome; Young Adult | 2020 |
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam.
Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Probiotics; Proton Pump Inhibitors; Vietnam | 2020 |
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Proton Pump Inhibitors; Rabeprazole; Sucralfate | 2020 |
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome; Turkey | 2020 |
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Health Plan Implementation; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Slovenia | 2021 |
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Pilot Projects; Prospective Studies | 2021 |
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Resistance, Bacterial; Europe; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Tetracycline; Young Adult | 2021 |
Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors | 2021 |
Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Tetracycline; Treatment Outcome; Turkey | 2021 |
Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2021 |
Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Croatia; Cross-Sectional Studies; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Physicians, Primary Care; Proton Pump Inhibitors; Students, Medical | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2021 |
Fixed drug eruption due to bismuth during Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Eruptions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rhode Island; Rifabutin; Tetracycline; Young Adult | 2021 |
Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Liver Transplantation; Transplant Recipients | 2021 |
Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.
Topics: Anti-Bacterial Agents; Benzene Derivatives; Bismuth; Cross-Over Studies; Drug Therapy, Combination; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Male; Metronidazole; Republic of Korea; Tetracycline | 2021 |
Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Treatment Outcome | 2021 |
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report.
Topics: Anti-Bacterial Agents; Bismuth; DNA, Bacterial; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Middle Aged; Penicillins; Recurrence; Retreatment; Treatment Outcome | 2021 |
Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Male; Middle Aged; Proton Pump Inhibitors; Registries | 2021 |
Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; China; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; RNA, Ribosomal, 16S | 2021 |
Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
Topics: Amoxicillin; Anti-Bacterial Agents; Bibliometrics; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2021 |
Effect of gastric microbiota on quadruple
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2021 |
Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proteomics | 2021 |
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyloric Antrum; Stomach | 2017 |
Barry Marshall, MD: H pylori 35 Years Later.
Topics: Anniversaries and Special Events; Antacids; Anti-Bacterial Agents; Asthma; Bacterial Vaccines; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Nobel Prize; Organometallic Compounds; Peptic Ulcer; Probiotics; Salicylates; Stress, Psychological | 2017 |
The diagnosis and management of H. pylori infection in Singapore.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Singapore | 2017 |
Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hospitals; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Salvage Therapy; Spain; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult | 2017 |
Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Helicobacter Infections; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2017 |
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Tablets; Tetracycline; Time Factors; Treatment Failure | 2017 |
Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies | 2017 |
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Hospitals; Humans; Macrolides; Male; Middle Aged; Retrospective Studies; Spain; Treatment Failure; Young Adult | 2018 |
Bismuth-Induced Inactivation of Ferric Uptake Regulator from Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bismuth; DNA, Bacterial; Enzyme Inhibitors; Enzyme Stability; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Conformation; Protein Multimerization; Repressor Proteins | 2017 |
Is Double-Dose Esomeprazole With Bismuth Really Safe?
Topics: Bismuth; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors | 2017 |
Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure; United States | 2018 |
Comment on Helicobacter pylori eradication using metronidazole.
Topics: Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2018 |
H. pylori Infection: ACG Updates Treatment Recommendations.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2018 |
Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Incidence; Levofloxacin; Male; Middle Aged; Protective Factors; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Factors; Stomach Neoplasms | 2018 |
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Topics: Anti-Bacterial Agents; Bismuth; Demography; Drug Therapy, Combination; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Tetracycline; Treatment Outcome | 2018 |
[The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Nausea; Patient Compliance; Proton Pump Inhibitors; Retrospective Studies; Treatment Failure; Treatment Outcome | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes; Bismuth; Drug Therapy, Combination; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proteobacteria; Proton Pump Inhibitors; Tetracycline; Young Adult | 2018 |
Bismuth-based quadruple Helicobacter pylori eradication regimen alters the composition of gut microbiota.
Topics: Anti-Bacterial Agents; Bismuth; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans | 2018 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2018 |
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Topics: Adult; Alcohol Drinking; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Proton Pump Inhibitors; Treatment Failure | 2018 |
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Risk Factors; Tetracycline; Treatment Failure | 2019 |
[Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2019 |
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Registries; Treatment Outcome; Young Adult | 2020 |
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
Topics: Aged; Bismuth; Cohort Studies; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neurotoxicity Syndromes; Organometallic Compounds; Tetracycline; Treatment Failure | 2019 |
Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes.
Topics: Adult; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Macrolides; Male; Middle Aged; Prognosis; Proton Pump Inhibitors; Retrospective Studies | 2019 |
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Young Adult | 2019 |
The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults.
Topics: Adult; Anti-Bacterial Agents; Asymptomatic Diseases; Bacteria; Bismuth; Female; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Young Adult | 2019 |
Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Outcome and Process Assessment, Health Care; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; United States | 2019 |
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Macrolides; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quinolones; Tetracycline; Young Adult | 2019 |
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; China; Drug Hypersensitivity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Penicillins; Prospective Studies; Treatment Outcome | 2019 |
Synthesis and characterisation of bismuth(III) aminoarenesulfonate complexes and their powerful bactericidal activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Organometallic Compounds | 2013 |
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Failure | 2014 |
Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Chlorides; Chronic Disease; Clarithromycin; Drug Resistance, Bacterial; Dyspepsia; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Peptic Ulcer; Salicylates; Zinc Compounds | 2014 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metaplasia; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Republic of Korea; Stomach Neoplasms; Tetracycline | 2013 |
Functional disruption of HypB, a GTPase of Helicobacter pylori, by bismuth.
Topics: Anti-Bacterial Agents; Bismuth; GTP Phosphohydrolases; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Multimerization | 2014 |
Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Retrospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2014 |
Preparation, characterization, and anti-Helicobacter pylori activity of Bi3+-Hericium erinaceus polysaccharide complex.
Topics: Anti-Bacterial Agents; Basidiomycota; Bismuth; Coordination Complexes; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Polysaccharides | 2014 |
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; Treatment Outcome | 2015 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome | 2015 |
First-line Bismuth-containing Five-day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Time; Treatment Outcome; Young Adult | 2016 |
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Barrett Esophagus; Bismuth; Breath Tests; Clarithromycin; Disease Management; Drug Therapy, Combination; Dyspepsia; Feces; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Italy; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms; Urea | 2015 |
Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prognosis; Salicylates; Thailand | 2015 |
Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Coordination Complexes; Crystallography, X-Ray; Helicobacter Infections; Helicobacter pylori; Humans; Hydrolysis; Hydroxamic Acids; Microbial Sensitivity Tests; Molecular Conformation | 2015 |
[Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Taste Disorders; Treatment Outcome; Young Adult | 2015 |
The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Pantoprazole; Pilot Projects; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Treatment Outcome | 2016 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Hospitals, Teaching; Humans; Levofloxacin; Logistic Models; Macrolides; Male; Middle Aged; Multivariate Analysis; Republic of Korea; Retrospective Studies; Tertiary Care Centers | 2016 |
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prevalence; Proton Pump Inhibitors; Retrospective Studies; RNA, Ribosomal, 23S; Treatment Failure; United States; Young Adult | 2016 |
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Humans; Male; Medication Adherence; Middle Aged; Minocycline; Prospective Studies; Rabeprazole; Treatment Outcome | 2016 |
[Quadruple therapy is more effective against H. pylori].
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2016 |
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2016 |
Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Canada; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Salvage Therapy; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Early Detection of Cancer; Evidence-Based Medicine; Fluoroquinolones; Gastritis; Gastrointestinal Microbiome; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Stomach; Stomach Neoplasms | 2017 |
Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure | 2017 |
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Urea | 2017 |
Second-line bismuth-containing quadruple therapy for
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Diabetes Mellitus, Type 2; Disease Eradication; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Retrospective Studies; Risk Factors; Tetracycline; Treatment Failure; Treatment Outcome | 2017 |
Oral and intravenous eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Hemorrhage; Humans; Infusions, Intravenous; Male; Metronidazole; Middle Aged; Pilot Projects; Ranitidine; Treatment Outcome | 2009 |
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Neoplasms; Tetracycline | 2009 |
[Guidelines of treatment for non-bleeding peptic ulcer disease].
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Histamine Antagonists; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2009 |
Bismuth salts in the treatment of Helicobacter pylori infection in children.
Topics: Adolescent; Bismuth; Child; Child, Preschool; Helicobacter Infections; Humans; Organometallic Compounds; Treatment Outcome | 2010 |
Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Calorimetry, Differential Scanning; Coordination Complexes; Drug Stability; Helicobacter Infections; Helicobacter pylori; Ketoprofen; Microbial Sensitivity Tests; Sulindac; Thermogravimetry | 2010 |
Contribution to the study of the chemical constitution of dermatol and airol.
Topics: Antacids; Antidiarrheals; Bismuth; Helicobacter Infections | 1947 |
The C terminus of HspA--a potential target for native Ni(II) and Bi(III) anti-ulcer drugs.
Topics: Amino Acid Sequence; Antacids; Anti-Ulcer Agents; Bacterial Proteins; Binding Sites; Bismuth; Circular Dichroism; Heat-Shock Proteins; Helicobacter Infections; Helicobacter pylori; Histidine; Humans; Nickel; Nuclear Magnetic Resonance, Biomolecular; Oligopeptides; Potentiometry; Protein Structure, Tertiary; Spectrophotometry, Ultraviolet | 2010 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Organometallic Compounds; Proton Pump Inhibitors; Salicylates | 2010 |
Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Treatment Outcome | 2010 |
Empiric therapies for Helicobacter pylori infections.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2011 |
Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline; Treatment Outcome | 2011 |
Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2011 |
Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori.
Topics: Bacterial Proteins; Bismuth; Citric Acid Cycle; Fumarate Hydratase; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Structure, Tertiary | 2012 |
Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Metronidazole; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2011 |
Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Breath Tests; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Minocycline; Phenotype; Proton Pump Inhibitors; Time Factors | 2012 |
Double-liposome-based dual-drug delivery system as vectors for effective management of peptic ulcer.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Stability; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Liposomes; Male; Microbial Sensitivity Tests; Particle Size; Peptic Ulcer; Ranitidine; Rats | 2012 |
Remarkable in vitro bactericidal activity of bismuth(III) sulfonates against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Coordination Complexes; Crystallography, X-Ray; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Molecular Conformation; Sulfonic Acids | 2012 |
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hispanic or Latino; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Tetracycline; Texas; Time Factors; Treatment Outcome; Urea | 2012 |
[The difference of the bismuth absorption from a single colloidal bismuth pectin therapy and quadruple therapy for eradicating Helicobacter pylori infection].
Topics: Absorption; Animals; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Male; Pectins; Rats; Rats, Wistar | 2002 |
[Ranitidine-bismuth citrate versus omeprazole plus two antibiotics for seven days for the eradication of Helicobacter pylori: a non-concluding clinical essay].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine | 2002 |
Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 2002 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 2003 |
Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine | 2003 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Treatment Outcome | 2003 |
Information from your family doctor. Ulcers and Helicobacter pylori infection.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Family Practice; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Ranitidine | 2003 |
[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Retreatment; Tetracycline | 2004 |
Sequential therapy for H. pylori: an 'aberrant' therapy ready for general use.
Topics: Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 2004 |
[Effect of acid suppression therapy for eradicating Helicobacter pylori infection on bismuth absorption from colloidal bismuth pectin].
Topics: Amoxicillin; Animals; Antacids; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Pectins; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].
Topics: Absorption; Amoxicillin; Animals; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Omeprazole; Organometallic Compounds; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Tetracycline | 2005 |
How effective are quadruple therapies as first-line H. pylori eradication therapies?
Topics: Adult; Anti-Infective Agents; Australia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Metronidazole; Netherlands; Omeprazole; Tetracycline; Treatment Outcome | 2005 |
Inhibition of jack bean urease by organobismuth compounds.
Topics: Antifungal Agents; Bismuth; Fabaceae; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Molecular Structure; Organometallic Compounds; Saccharomyces cerevisiae; Structure-Activity Relationship; Urease | 2006 |
Helicobacter pylori treatment: a practical approach.
Topics: Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Ofloxacin; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Polymerase Chain Reaction; Ranitidine; Treatment Outcome | 2005 |
Review of successful treatment for Helicobacter species in laboratory mice.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Infective Agents; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Feces; Female; Helicobacter; Helicobacter Infections; Metronidazole; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Polymerase Chain Reaction; Pregnancy; Rodent Diseases | 2006 |
Helicobacter pylori eradication in peptic dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine | 2005 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs.
Topics: Amino Acid Sequence; Anti-Ulcer Agents; Bacterial Proteins; Binding Sites; Bismuth; Cysteine; Helicobacter Infections; Klebsiella; Models, Molecular; Molecular Sequence Data; Nuclear Magnetic Resonance, Biomolecular; Plant Proteins; Protein Conformation; Sequence Alignment; Sulfhydryl Compounds; Urease | 2006 |
Comparison of stool enzyme immunoassay and immunochromatographic method for detecting Helicobacter pylori antigens before and after eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antigens, Bacterial; Bismuth; Chromatography; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoenzyme Techniques; Male; Middle Aged; Proton Pump Inhibitors; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2006 |
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Retrospective Studies; Salicylates; Treatment Outcome | 2006 |
Results from the pediatric European register for treatment of Helicobacter pylori (PERTH).
Topics: Adolescent; Antacids; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Male; Microbial Sensitivity Tests; Omeprazole; Registries; Treatment Outcome | 2007 |
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Medication Adherence; Metronidazole; Pantoprazole; Tetracycline | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Colombia; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metaplasia; Metronidazole; Organometallic Compounds; Precancerous Conditions; Regression Analysis; Salicylates; Smoking; Treatment Failure | 2007 |
A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori: implication for nickel homeostasis and bismuth susceptibility.
Topics: Bacterial Proteins; Bismuth; Chaperonins; Dimerization; Edetic Acid; Escherichia coli; Heat-Shock Proteins; Helicobacter Infections; Helicobacter pylori; Histidine; Hydrogen-Ion Concentration; Metalloproteins; Nickel; Protein Binding; Protein Structure, Quaternary; Protein Structure, Tertiary; Recombinant Proteins | 2008 |
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Cecal Diseases; Cecum; Chronic Disease; Helicobacter; Helicobacter Infections; Hepatitis, Animal; Inflammation; Liver; Male; Metronidazole; Mice; Mice, SCID; Neomycin; Rodent Diseases; Tetracycline | 1995 |
[Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment?].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pepsinogens; Prospective Studies; Radioimmunoassay; ROC Curve; Sensitivity and Specificity; Stomach; Tetracycline; Time Factors | 1995 |
[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline; Time Factors | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline | 1995 |
Eczema responsive to treatment for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Eczema; Gastroenteritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1995 |
Evaluation of antibiotic therapies for eradication of Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred Strains; Molecular Sequence Data; Random Allocation; Stomach Diseases; Tetracycline | 1995 |
The role of serology in the diagnosis of Helicobacter pylori infection in children.
Topics: Adolescent; Age Factors; Amoxicillin; Bismuth; Child; Child, Preschool; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Immunologic Tests; Infant; Korea; Male; Penicillins | 1995 |
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Gastroenterology; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medical Staff, Hospital; Microbial Sensitivity Tests; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Recurrence; Stomach Ulcer; United Kingdom | 1995 |
[Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Duodenitis; Evaluation Studies as Topic; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Stomach Ulcer; Time Factors | 1995 |
Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Antibodies, Bacterial; Bismuth; Child; Child, Preschool; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Metronidazole; Organometallic Compounds; Polymerase Chain Reaction; Recurrence; Salicylates; Stomach Ulcer | 1995 |
"Cure" of Helicobacter pylori and "cure" of peptic ulcer: do they mean the same thing?
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1995 |
Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child.
Topics: Adolescent; Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Remission Induction; Stomach Neoplasms | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests | 1995 |
Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media.
Topics: Agar; Animals; Bacteriological Techniques; Bismuth; Blood; Cattle; Culture Media; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Sheep; Starch | 1995 |
Helicobacter pylori: a human pathogen.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1995 |
Treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline | 1995 |
Helicobacter pylori infection and gastric juice vitamin C levels. Impact of eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Bismuth; Drug Therapy, Combination; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Stomach Neoplasms | 1995 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrin-Releasing Peptide; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptides | 1994 |
Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation.
Topics: Adult; Aged; Bismuth; Cell Division; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metaplasia; Metronidazole; Middle Aged; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Pyloric Antrum; Tetracycline | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Failure; Treatment Outcome | 1994 |
Short report: evaluation of Helicobacter pylori eradication with bismuth sucralfate.
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Sucralfate; Treatment Failure | 1994 |
[Cost-benefit analysis of conservative therapy of gastritis and peptic ulcer].
Topics: Absenteeism; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 1994 |
[10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Time Factors | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Norway; Omeprazole; Oxytetracycline; Peptic Ulcer | 1994 |
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Topics: Adult; Aged; Bile Acids and Salts; Bismuth; Choline; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Phospholipases A; Phospholipases A2; Phospholipids | 1994 |
Preservation of gastric antral mucus is associated with failure of eradication of Helicobacter pylori by bismuth, metronidazole and tetracycline.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Administration Schedule; Female; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neutrophils; Pyloric Antrum; Tetracycline | 1994 |
Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline; Time Factors | 1994 |
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Peptic Ulcer; Salicylates | 1994 |
Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Insulin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Time Factors | 1994 |
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Protein-Losing Enteropathies; Salicylates | 1994 |
H. pylori and ulcers.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Ranitidine; Recurrence; Salicylates; Stomach Ulcer | 1994 |
Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment.
Topics: Amoxicillin; Ascorbic Acid; Bismuth; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Salicylates; Smoking | 1994 |
[Helicobacter and peptic ulcer: history, diagnosis and therapy--when, in whom and how?].
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Tetracycline | 1994 |
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing.
Topics: Adult; Bismuth; Female; Food; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Peptic Ulcer; Protein Precursors; Protein Processing, Post-Translational; Salicylates; Tetracycline | 1993 |
Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies.
Topics: Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Organometallic Compounds; Phospholipases A; Phospholipases A1; Phospholipases A2; Stomach Ulcer; Type C Phospholipases | 1993 |
Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis.
Topics: Adult; Biopsy; Bismuth; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Pepsinogens; Salicylates | 1993 |
[Helicobacter pylori infection and peptic ulcer].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracycline | 1993 |
Detection of H. pylori in saliva using a monoclonal antibody.
Topics: Adolescent; Adult; Amoxicillin; Antibodies, Bacterial; Antibodies, Monoclonal; Bismuth; Child; Child, Preschool; Fluorescent Antibody Technique; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Mouth Mucosa; Saliva | 1993 |
Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children.
Topics: Adolescent; Amoxicillin; Biopsy; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Pyloric Antrum; Recurrence; Salicylates; Time Factors; Treatment Outcome | 1993 |
[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Ranitidine; Salicylates; Tetracycline | 1993 |
Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Tetracycline | 1993 |
Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.
Topics: Acute Disease; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Parietal Cells, Gastric; Tetracycline | 1993 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Metronidazole; Neutrophils; Prospective Studies; Recurrence; Stomach Ulcer | 1993 |
Long-term Helicobacter pylori recurrence after successful eradication with triple therapy.
Topics: Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1993 |
Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Citrates; Dogs; Ethanol; Female; Ferrets; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Indomethacin; Isoenzymes; Male; Microbial Sensitivity Tests; Organometallic Compounds; Pepsin A; Ranitidine; Rats; Stomach Ulcer | 1993 |
[The effect of colloidal bismuth and its combination with amoxicillin on the elimination of Helicobacter pylori in patients with a duodenal ulcer and chronic antral gastritis].
Topics: Adult; Aged; Amoxicillin; Bismuth; Chronic Disease; Colloids; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pyloric Antrum | 1993 |
Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors.
Topics: Animals; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Disease Models, Animal; Ferrets; Helicobacter Infections; Urease | 1993 |
Eradication of Helicobacter pylori normalizes serum gastrin concentration and antral gastrin cell number in a patient with primary gastrin cell hyperplasia.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Male; Metronidazole; Middle Aged; Pyloric Antrum; Tetracycline | 1993 |
Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Cimetidine; Esophagitis; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Pyloric Antrum; Ranitidine | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins; Male; Metronidazole; Middle Aged; Omeprazole; Pyloric Antrum; T-Lymphocytes; Tetracycline | 1993 |
Response to article by Forné et al.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Remission Induction | 1996 |
[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Tetracycline; Time Factors | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; Contraindications; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Mice; Mice, Inbred BALB C; Mice, Nude; Penicillins; Peptic Ulcer; Recurrence; Severity of Illness Index; Treatment Outcome | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Omeprazole; Patient Compliance; Penicillins; Recurrence; Tetracycline; Time Factors | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Penicillins; Sex Factors; Smoking; Tetracycline; Time Factors; Wound Healing | 1996 |
Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
Topics: Bismuth; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Salivary Gland Neoplasms | 1996 |
Management of Helicobacter pylori-positive peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1996 |
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine; Recurrence; Time Factors | 1996 |
Helicobacter pylori reinfection after apparent eradication--the Ipswich experience.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Case-Control Studies; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; England; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Recurrence; Stomach Ulcer; Time Factors; Urea | 1996 |
Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents.
Topics: Administration, Topical; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Intubation, Gastrointestinal; Metronidazole; Penicillins | 1996 |
Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Diet; Drinking; Female; Helicobacter; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred A; Mice, Inbred DBA; Molecular Sequence Data; Polymerase Chain Reaction; Rodent Diseases; Tetracycline | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline | 1996 |
[Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Gastritis; Germany; Helicobacter Infections; Humans; Peptic Ulcer; Stomach Neoplasms; Treatment Outcome | 1996 |
Reflections on gastric ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Recurrence; Salicylates; Stomach Ulcer | 1996 |
[Triple-therapy treatment during 1 month versus 2 weeks in gastroduodenal disease due to Helicobacter pylori in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Time Factors | 1996 |
The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results.
Topics: Adult; Amoxicillin; Bacteria; Bismuth; Breath Tests; Colon; Drug Therapy, Combination; Eating; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Sucralfate; Urea | 1995 |
Practice guidelines for treatment of peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Peptic Ulcer; Practice Guidelines as Topic; Ranitidine | 1996 |
Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gastric Juice; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Insulin-Like Growth Factor I; Male; Metronidazole; Middle Aged | 1996 |
Pylorid, H. pylori and peptic ulcer.
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Randomized Controlled Trials as Topic; Ranitidine | 1996 |
[Connection between Helicobacter pylori infection and chronic gastrointestinal urticaria].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Bismuth; Chronic Disease; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Penicillins; Urticaria | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome | 1996 |
Ranitidine bismuth citrate therapy.
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1996 |
[Anti-Helicobacter pylori therapy. Who should be treated, how, how long?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Treatment Outcome | 1996 |
[Is gastric acid secretion inhibition necessary for successful eradication of Helicobacter pylori?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastric Acidity Determination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Recurrence; Salicylates; Stomach Ulcer; Time Factors; Tinidazole | 1996 |
Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Cost of Illness; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Pilot Projects; Salicylates; Tetracycline | 1996 |
Treating Helicobacter pylori--the best is yet to come?
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline | 1996 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 1997 |
Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Risk Factors; Smoking; Stomach Ulcer; Sucralfate; Wound Healing | 1997 |
Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis.
Topics: Amoxicillin; Bismuth; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged | 1997 |
Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1997 |
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Spectrometry; Metronidazole; Middle Aged; Omeprazole; Sensitivity and Specificity; Tetracycline | 1997 |
Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Vaccination | 1997 |
Identification and eradication of Helicobacter pylori in an isolated patient population.
Topics: Amoxicillin; Bismuth; Cost Savings; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Military Personnel; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States; Utah | 1997 |
Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular?
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitrichomonal Agents; Bismuth; Chaperonin 60; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epithelium; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; HLA-DR Antigens; Humans; Immunohistochemistry; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Time Factors | 1997 |
Treatment of gastritis in cheetahs (Acinonyx jubatus).
Topics: Acinonyx; Animals; Anti-Bacterial Agents; Antitrichomonal Agents; Biopsy; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Gram-Negative Bacterial Infections; Helicobacter; Helicobacter Infections; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Salicylates; Sensitivity and Specificity; Tetracycline; Time Factors | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets.
Topics: Amoxicillin; Animals; Antacids; Bacterial Proteins; Biopsy; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Ferrets; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter; Helicobacter Infections; Metronidazole; Organometallic Compounds; Recurrence; Salicylates; Time Factors; Urease | 1996 |
Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets.
Topics: Amoxicillin; Animals; Antacids; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Female; Ferrets; Gastritis; Helicobacter; Helicobacter Infections; Male; Metronidazole; Organometallic Compounds; Salicylates; Specific Pathogen-Free Organisms | 1996 |
An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Imipenem; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Tetracycline | 1996 |
Cure of Helicobacter pylori: a hidden curse?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Risk Factors; Salicylates; Sex Factors; Weight Gain | 1997 |
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer | 1998 |
Helicobacter pylori: challenges for the paediatrician.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Urea | 1997 |
Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Male; Omeprazole; Organometallic Compounds; Penicillins; Salicylates | 1998 |
Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease.
Topics: Bismuth; Drug Interactions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline | 1998 |
The ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Spain; Tetracycline | 1998 |
Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Time Factors | 1998 |
Peptic ulcer treatment today--is there a role for maintenance therapy?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence | 1997 |
[Polyneuropathy caused by vitamin B12 deficiency secondary to chronic atrophic gastritis and giardiasis].
Topics: Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Antiprotozoal Agents; Bismuth; Duodenitis; Enzyme Inhibitors; Evoked Potentials, Somatosensory; Female; Gastritis, Atrophic; Giardiasis; Helicobacter Infections; Helicobacter pylori; Humans; Hydroxocobalamin; Malabsorption Syndromes; Metronidazole; Middle Aged; Neural Conduction; Omeprazole; Peripheral Nervous System Diseases; Remission Induction; Vitamin B 12 Deficiency | 1998 |
Clostridium difficile colitis associated with treatment of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Penicillins; Salicylates; Stomach Diseases | 1998 |
[Evaluation of results of surgical treatment of peptic ulcer associated with Helicobacter pylori].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach Ulcer | 1998 |
National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Child; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Health Care Surveys; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Imidazoles; Macrolides; Male; Middle Aged; Penicillins; Proton Pump Inhibitors; Tetracyclines | 1998 |
The European meeting on Helicobacter pylori: therapeutic news from Lisbon.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Portugal; Proton Pump Inhibitors; Ranitidine | 1998 |
Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Vaccines; Bismuth; Drug Design; Drug Therapy, Combination; Duodenitis; Forecasting; Gastritis; Genome, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 1998 |
Helicobacter pylori eradication failure--'salvage' therapies needed.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Treatment Failure | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine | 1998 |
In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitrofurantoin; Tetracycline | 1998 |
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; New York City; Organometallic Compounds; Peptic Ulcer; Prisons; Ranitidine; Retrospective Studies; Salicylates; Tetracycline; Urban Health | 1998 |
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Child; Disease Progression; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1999 |
A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Delivery Systems; Helicobacter Infections; Metronidazole; Solubility; Stomach Ulcer; Tablets, Enteric-Coated; Tetracycline | 1999 |
Attenuation of hydrophobic phospholipid barrier is an early event in Helicobacter felis-induced gastritis in mice.
Topics: Animals; Bismuth; Disease Models, Animal; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Hydrogen-Ion Concentration; Mice; Mice, Inbred C57BL; Organ Size; Phosphatidylcholines; Phospholipases A; Phospholipases A2; Phospholipids; Stomach | 1999 |
Helicobacter pylori eradication treatment reduces the severity of rosacea.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A; Immunoglobulin G; Male; Metronidazole; Middle Aged; Organometallic Compounds; Rosacea; Treatment Outcome | 1999 |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tetracycline | 1999 |
Duodenal ulcer disease: to treat H. pylori infection or not?
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ranitidine; Tetracycline; United States | 1992 |
Organobismuth compounds: activity against Helicobacter pylori.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Inorganic Chemicals; Microbial Sensitivity Tests; Organic Chemicals; Peptic Ulcer | 1999 |
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bacterial Vaccines; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Escherichia coli Proteins; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Metronidazole; Omeprazole; Organometallic Compounds; Recombinant Proteins; Salicylates; Saliva; Urease | 1999 |
Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline | 1999 |
[Intensifying the study of the proper treatment of digestive ulceration].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer | 1997 |
Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Elapid Venoms; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Phospholipases A; Phospholipases A2; Ranitidine | 1999 |
The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Esophagitis; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Severity of Illness Index | 1999 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Biopsy; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Cat Diseases; Cats; Clarithromycin; Female; Gas Chromatography-Mass Spectrometry; Helicobacter; Helicobacter Infections; Male; Metronidazole; Polymerase Chain Reaction; Prospective Studies; Random Allocation; Ranitidine; Stomach Diseases; Tinidazole; Urea | 1999 |
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Staging; Omeprazole; Organometallic Compounds; Prospective Studies; Remission Induction; Salicylates; Stomach Neoplasms | 1999 |
Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.
Topics: Bacterial Proteins; Bismuth; Carrier Proteins; Cation Transport Proteins; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Membrane Proteins; Metals, Heavy; Microbial Sensitivity Tests; Organometallic Compounds; Proteins; Ranitidine | 1999 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tests; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Sensitivity and Specificity; Urea | 1999 |
Treatment of Helicobacter pylori: where are we now? What are the key questions?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Ranitidine; Stomach Ulcer; Treatment Outcome; United Kingdom | 1999 |
Re-treatment after Helicobacter pylori eradication failure.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Treatment Failure | 1999 |
Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Chronic Disease; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates | 1999 |
Therapy and diagnostic tests used for Helicobacter pylori infection in the Scandinavian countries in 1998.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Diseases; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Practice Patterns, Physicians'; Proton Pump Inhibitors; Scandinavian and Nordic Countries; Serologic Tests | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Mixed Function Oxygenases; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Synthesis Inhibitors; Treatment Outcome | 1999 |
Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lactose; Liver Function Tests; Macaca mulatta; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Sialic Acids | 1999 |
[Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; L-Lactate Dehydrogenase; Metronidazole; Omeprazole; Organometallic Compounds; Purpura, Thrombocytopenic, Idiopathic; Salicylates; Tetracycline | 1999 |
Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Chemoprevention; Colombia; Follow-Up Studies; Gastritis, Atrophic; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Penicillins; Precancerous Conditions; Salicylates; Stomach Neoplasms; Treatment Failure; Virulence | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States | 2000 |
Helicobacter pylori eradication in clinical practice: retreatment rates and costs of competing regimens.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Retrospective Studies | 2000 |
[IgG and IgA immunoglobulins in helicobacter pylori infections of children with chronic dyspepsia before and after two week triple drug therapy].
Topics: Adolescent; Amoxicillin; Bismuth; Blotting, Western; Child; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Enzyme-Linked Immunosorbent Assay; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monitoring, Physiologic; Ranitidine; Serologic Tests | 1999 |
Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Male; Microbial Sensitivity Tests; Organometallic Compounds; Predictive Value of Tests; Solubility | 2000 |
Single drug therapy for Helicobacter pylori infection.
Topics: Bismuth; Capsules; Drug Combinations; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2000 |
Pooled analysis of Helicobacter pylori eradication regimes in Asia.
Topics: Asia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2000 |
Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Ranitidine; Salicylates | 2000 |
Strategies to treat patients with antibiotic resistant Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2000 |
[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].
Topics: Anti-Ulcer Agents; Bismuth; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Tetracycline; Treatment Failure | 2000 |
Dual therapy with ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Peptic Ulcer; Ranitidine | 2001 |
Optimal strategy of treatment of Helicobacter pylori infection: renaissance of antisecretory drugs?
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 2001 |
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Patient Care Planning; Penicillins; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine; Treatment Outcome | 2001 |
In search of the Holy Grail of Heliocobacter pylori remedies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Humans; Metronidazole; Pilot Projects; Ranitidine; Spain | 2001 |
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitroimidazoles; Ranitidine; Treatment Outcome | 2001 |
Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bismuth; DNA Fingerprinting; Duodenal Ulcer; Female; Flagellin; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Ranitidine; Recurrence; Restriction Mapping; Species Specificity; Time Factors; Urease | 2001 |
What is the most effective regimen for eradication of Helicobacter pylori in patients who have failed a first eradication attempt?
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Costs; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Meta-Analysis as Topic; Proton Pump Inhibitors; Ranitidine | 2002 |
Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.
Topics: Animals; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Mice; Mice, Inbred C57BL; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
Use of an ammonia electrode for rapid quantification of Helicobacter pylori urease: its use in the endoscopy room and in the assessment of urease inhibition by bismuth subsalicylate.
Topics: Ammonia; Bismuth; Electrodes; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; In Vitro Techniques; Male; Middle Aged; Organometallic Compounds; Salicylates; Sensitivity and Specificity; Urease | 1992 |
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Eradicating Helicobacter pylori.
Topics: Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Gastric Mucins; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Middle Aged; Organometallic Compounds; Solubility | 1992 |
Quantitative assessment of histological changes in chronic gastritis after eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Tinidazole | 1992 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Microbial; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Prevalence; Prospective Studies; Stomach; Tinidazole; United Arab Emirates | 1992 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Ranitidine; Recurrence; Salicylates; Tetracycline | 1992 |
[Eradicate Helicobacter pylori at any price?].
Topics: Bismuth; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Recurrence | 1992 |
Management and response to treatment of Helicobacter pylori gastritis.
Topics: Age Factors; Ampicillin; Antacids; Biopsy; Bismuth; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence; Prospective Studies; Sex Factors; Socioeconomic Factors | 1992 |
Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Tetracycline | 1992 |
[Helicobacter pylori: from harmless commensal to clinically significant disease factor].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence; Stomach Ulcer; Tetracycline | 1992 |
[Helicobacter pylori infections in children].
Topics: Adolescent; Amoxicillin; Antacids; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds | 1992 |
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Regression Analysis; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
[Helicobacter pylori and erosive lesions of the gastric mucosa in cirrhosis].
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Liver Cirrhosis; Stomach Diseases | 1991 |
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach; Time Factors | 1991 |
Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin.
Topics: Adult; Bismuth; Breath Tests; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Nitrofurantoin; Organometallic Compounds; Salicylates; Urea | 1991 |
Helicobacter pylori infection in uraemic patients.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Prevalence; Uremia | 1991 |
Epidemiology and treatment of gastric Campylobacter pylori infection: more questions than answers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Diagnosis, Differential; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Organometallic Compounds; Prevalence; Salicylates; Tinidazole; Urease | 1990 |
Long-term follow-up of voluntary ingestion of Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Recurrence; Salicylates | 1991 |
Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dinoprostone; Duodenitis; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Salicylates | 1991 |
Helicobacter pylori.
Topics: Bismuth; Child; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Salicylates | 1991 |
[Assessment of the efficacy of de-nol and bismuth subnitrate treatment of patients with associated peptic ulcer and pyloric Helicobacter infection (experimental and clinical studies)].
Topics: Adult; Animals; Anti-Ulcer Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Scanning; Middle Aged; Organometallic Compounds; Peptic Ulcer; Pyloric Antrum; Rats | 1991 |
On: The who's and when's of therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1991 |
[Helicobacter pylori, peptic diseases and colloid bismuth].
Topics: Bismuth; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1990 |
Systemic chemotherapy for Helicobacter pylori eradication?
Topics: Administration, Oral; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Salicylates | 1990 |